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The pathogenesis of many orthopaedic infections is related to the presence of 
biofilms on device surfaces, which are currently combatted, primarily by use 
conventional antibiotic therapies once the infection has occurred. However, the 
overuse and misuse of antibiotics has led to antimicrobial resistance (AMR) and 
therefore it is of great important to develop non-antibiotic approaches to efficiently 
treat biofilm-related bacterial infection for orthopaedic applications.  
In this study, two different materials were investigated that are relevant to 
orthopaedic applications: titanium (Ti, non-degradable) and 
polycaprolactone/gelatine (PCL/GT, degradable). NO is used as an efficient 
antibacterial and antibiofilm agent as well as acting as a regulator of bone tissue 
engineering. Three NO-releasing systems have been designed and fabricated. The 
mechanisms of NO release kinetics and the antimicrobial properties of these systems 
are the key points to study in the main experimental chapters. The chemical 
modification of NO-releasing coatings on three platforms inhibits bacterial adhesion, 
resulting in impediment of biofilm formation on surfaces. 
In Chapter 3, NO-releasing flat Ti surfaces were developed for antibiofilm and bone-
integrating studies. Two different aminosilane precursors (6-Aminohexyl-3-
aminopropyl trimethoxysilane (AHAP3) and 11-Aminoundecyltriethoxysilane (AUTES)) 
were immobilised onto the surface allowing the necessary amino functionality 
required to subsequently tether diazeniumdiolates. The structure of aminosilane 
precursors affected the resultant NO releasing properties in terms of payload and 
release kinetics. Both AHAP3/NO and AUTES/NO displayed similar biofilm inhibition 
efficiency against Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. 
aeruginosa) after 6 h. And AUTES/NO was shown not to be cytotoxic towards human 
primary bone cells.  
In Chapter 4, Ti foams were fabricated with a novel Lost Carbonate Sintering (LCS) 
process, and different layers of AUTES (the best performing silane precursor in 
Chapter 3) have been used as aminosilane precursors to silanise the Ti foams. The 
layers of AUTES played roles on the NO-releasing kinetics and the antimicrobial 
efficacy of the Ti foams. 5%AUTES/NO displayed the optimal 
antibiofilm/antimicrobial properties against both Escherichia coli (E. coli) and S. 
aureus after 4 and 24 h. 
In Chapter 5, electrospun biodegradable scaffolds functionalised with NO were 
evaluated for their antimicrobial properties and bone cytocompatibility. Five ratios 
of PCL/GT polymer blends were electrospun into membranes and crosslinked with 
varying concentrations of genipin to control the degradation profile. The addition of 
PCL and crosslinking process improved the microstructure and the wettability of the 
membranes. In antibiofilm tests against E. coli and S. aureus, the crosslinked NO-
releasing membrane that contained more gelatine displayed higher efficacy on both 
surface biofilm inhibition after 4 h owing to the higher loading of NO on these 
membranes. The crosslinked NO-releasing membranes with longer degradation 
profiles also performed better in terms of antibacterial response than the non-
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Chapter 1: Introduction  
  
Orthopaedic implants are widely used for fixation of long bone fracture, correction 
and stabilisation of spine deformities, replacement of joints, and cranio-maxillofacial 
applications. According to National Joint Registry,1 for joint replacements alone over 
2.5 million surgeries have been performed in the UK, and the number is still growing 
annually, especially given the increase the ageing demographic. The result of this is a 
significant economic burden on the NHS. Furthermore, morbidity and mortality rates 
may actually increase implants fail. Two leading causes of orthopaedic implant failure 
are aseptic loosening (18%) and infection (20%).2 Aseptic loosening originates from 
poor integration of implants. Infections result from pathogens (mainly biofilm-
forming bacteria) on implant surfaces, in which, Staphylococcus species, prominently 
Staphylococcus aureus (S. aureus) and Staphylococcus epidermidis (S. epidermis), 
account for approximately 70% of the infections. Pseudomonas aeruginosa (P. 
aeruginosa) accounts for another 8%.3 Escherichia coli (E. coli) is also one of the most 
frequently isolated microorganism in orthopaedic implant infections with a portion 
of approximately 6-23%.4-5  
The pathogenesis of many orthopaedic infections is related to the presence of 
biofilms on device surfaces, and current, primary treatment involves the use of 
conventional antibiotic therapy which can lead to antimicrobial resistance (AMR).6 
Once a biofilm forms on a surface it is much more difficult to eradicate than 
planktonic bacteria as biofilm cells are inherently more tolerant to antibiotics (up to 
1000x higher concentration of antibiotics are needed to achieve efficient 
treatment).7-8 The overuse and misuse of antibiotics has however resulted in the rise 
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of AMR which necessitates larger doses and last resort antibiotics for treatment. 
AMR is predicted to kill 10 million people annually by 2050 and have a global 
economic burden of over 100 trillion USD.9 Moreover, no new classes of antibiotic 
have been discovered since 1987.10 As such there is an urgent need to develop new 
alternatives to antibiotics that can treat infections without contributing to AMR.  
In the body of this thesis, non-antibiotic antimicrobial materials, with specific focus 
on nitric oxide (NO)-releasing materials are designed and fabricated for potential 
orthopaedic applications. 
1.1 Aims and Objectives 
NO is a potent antimicrobial agent that is produced endogenously as a response to 
invading pathogens and not developing antimicrobial resistance. The antimicrobial 
efficacy of NO is dependent upon the NO release kinetics, resulting from NO delivery 
strategy. Both the antimicrobial capacity and cytotoxicity of NO are needed to be 
concerned in designing NO release platforms for biomedical applications. The aim of 
this thesis is to develop NO releasing systems that can treat infections on non-
degradable (titanium) and degradable (electrospun membranes) surfaces for use in 
orthopaedic implant material development.  
The aim of this thesis is achieved via these objectives:  
1. To fabricate a range of bone-integrating, silane-modified titanium implant 
surfaces that can release NO for the purpose of treating orthopaedic 
infections without the use of antibiotics 
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2. To investigate the mechanism of NO release of these silane-modified NO 
releasing surfaces in order to control the rate and payload of active agent 
delivered. 
3. To investigate the feasibility of tethering NO-releasing silane-precursor 
molecules onto titanium foams fabricated using lost carbon sintering (LCS) as 
a viable antimicrobial bone-integrating porous scaffold. 
4. To investigate the fabrication of a range of electrospun biodegradable 
PCL/gelatine scaffolds for bone tissue engineering applications. 
5. To investigate tethering of NO-releasing diazeniumdiolates, along with 
subsequent release kinetics and payload onto these electrospun scaffolds.  
6. To evaluate the antimicrobial efficacy and cytocompatibility of these NO 
releasing materials. 
1.2 Structure of the Thesis 
The structure of this thesis follows the antimicrobial structure design strategy, 
ranging from surfaces to porous structure to membranes, using different fabrication 
techniques. The chapter orders are as follows:  
• Chapter 2: Literature Review 
• Chapter 3: Nitric Oxide Releasing Titanium Surfaces for Antimicrobial Bone-
Integrating Orthopaedic Implants 
• Chapter 4: Antimicrobial Nitric Oxide Releasing Porous Titanium Foams 
• Chapter 5: Fabrication and Characterisation of Antimicrobial Guided Bone 
Regeneration (GBR) Electrospun Membranes 
• Chapter 6: Conclusions and Suggestions for Future Work 
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Chapter2: Literature Review  
2.1 Biofilm-Related Infections in Orthopaedic Implants 
2.1.1 Antimicrobial Resistance 
Antimicrobial resistance (AMR) is a substantial global challenge associated with high 
rates of morbidity and mortality.11-13 The misuse and overuse of antibiotics in clinical 
therapy for bacterial infection have been regarded as the primary drivers that causing 
AMR.14-16 It has been reported that the rate of the surgical failure in orthopaedic 
implants due to bacterial infection is approximately 20%.17 AMR occurs across 
worldwide regardless of the income level and inflicts the increasing clinical and 
financial burden.18 Currently, there are 700,000 deaths annually are attributed to 
AMR infections. It also has been estimated to have a globally rise to 10 million people 
die from AMR and 100 trillion USD costs by 2050 if current trends continue.9, 19 In the 
past 10 years, the World Health Organisation (WHO) and many other organisations 
have filed reports on the importance of studying and finding protocols in tackling the 
global rise of AMR.9, 19 
Bacterial resistance is intensively related to the abuse of antibiotic in hospitals or 
community. An increased mortality rates of patients with bloodstream infections has 
been reported to be associated with resistant Escherichia coli (E. coli), Pseudomonas 
aeruginosa (P. aeruginosa), Staphylococcus aureus (S. aureus) and Klebsiella 
pneumoniae (K. pneumoniae), etc.20 In addition, infections caused by the methicillin-
resistant S. aureus (MRSA) also has been widely observed in the community.21  
The resistance in bacteria that develop from initial antibiotic-sensitivity, but then 
gradually adapt, to ultimate antibiotic-resistance. When bacterial cells are exposed 
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to an antibiotic, susceptible cells will die, but those insensitive ones will survive. Once 
the insensitive cells are regrown, all of the bacterial cells in culture will be a resistant 
cluster.22 Figure 2.1 shows the formation of resistant bacterial cells.  
 
 
Figure 2.1: Growth of resistant bacterial cells. When cells are exposed to an antibiotic (could 
be repeated several times), the sensitive cells are killed and the survivals are resistant cells. 
All of the regrown cells are antibiotic resistant.22   
 
The resistance can be an intrinsic resistance or an acquired resistance in bacteria.23 
Intrinsic resistance is a general characteristic within one bacterial species with genes 
encoded with resistance mechanisms. For example, altering the permeability of the 
membrane and active drug efflux are two intrinsic resistance methods that bacteria 
have developed.24 While the acquired resistance which associates to resistance 
mechanisms of drug target modification, drug uptake limitation and drug efflux, 
relies on the resistance genes that transferred from other bacteria.25 Different origins 
of resistance work with different mechanisms. Therefore, the antimicrobial 
resistance mechanisms of bacterial cells can be divided into four categories: (1) 
antibiotic inactivation; (2) drug target modification; (3) altered permeability of cells; 
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(4) active drug efflux. The mechanism scheme is illuminated in Figure 2.2. As they 
have different structures, gram-negative bacteria (such as E. coli and P. aeruginosa) 
vary in terms of their resistance mechanisms in comparison with gram-positive 
bacteria (i.e. S. aureus). Gram-negative bacteria use the four resistance mechanisms 
listed above. Gram-positive bacteria on the other hand, lacking of lipopolysaccharide 
(LPS) outer membranes and thicker cell wall and therefore possess a limitation in 
using altered membrane permeability and drug efflux mechanisms.26-27  
 
 
Figure 2.2: Main mechanisms of antimicrobial resistance. Image reproduced from Reygaert 




2.1.2 Biofilm-related Infections 
Biofilms contribute to the spread of antimicrobial resistance. An established biofilm 
is a dynamic three-dimensional extracellular matrix (ECM) consisting of 
polysaccharides and proteins. Biofilms provide a protective environment for bacterial 
population, which is associated with resistance to antibiotic chemotherapy in 
subsequent infections.28 The first biofilm related infection was identified by 
Costerton29 and coworkers in 1982 using an electron microscopy study of S. aureus 
bloodstream infection. Since then, it has been found that bacterial biofilms could 
exist on almost all type of devices.30 Bacteria commonly isolated from the biofilms 
on medical devices include both gram-positive and gram-negative species.31 In terms 
of medical device, the main species of gram-positive bacteria include S. epidermidis 
and S. aureus; the common species of gram-negative bacteria are multidrug-resistant 
E. coli and P. aeruginosa. Some of the common medical devices that prone to biofilm 










Table 2.1: Common medical devices and biofilm related pathogen species. 
Medical Device Biofilm Related Bacteria Ref. 
Central venous catheters S. epidermidis, S. aureus, P. aeruginosa, 
Candida albicans, K. pneumoniae, and 
Enterococcus faecalis 
32-33 
Urinary catheters S. epidermidis, Enterococcus faecalis, E. coli, 
Proteus mirabilis, P. aeruginosa, K. 
pneumoniae 
34 
Contact lenses Acanthamoeba spp., P. aeruginosa 35-36 
Breast implants S. aureus, coagulase-negative 
staphylococci, 
Propionibacterium acnes and Citrobacter 
koseri 
37 
Prosthetic cardiac valves coagulase-negative staphylococci, S. 
aureus, Candida albicans and enterococci 
38 
Endotracheal tubes S. aureus, P. aeruginosa, Proteus 
mirabilis, and S. epidermidis 
39 
Orthopaedic implants P. aeruginosa, S. epidermis, S. aureus, P. 








Once a biofilm is formed on the surface of a medical device, they become difficult to 
remove and are less susceptible to a variety of physicochemical killing mechanisms, 
such as acidity, UV light, changes in salinity or hydration, heavy metal and 
phagocytosis.41-45 There are 5 stages of the biofilm formation which are illustrated in 
Figure 2.3: (1) initial reversible attachment of cells onto the surfaces; (2) production 
of ECM to solid the attachment; (3) early development of biofilm structure 
(microcolony); (4) maturation of biofilm; (5) dispersion of free-swimming cells from 
the biofilm into environment. After stage 5, some of the dispersed planktonic 
bacteria may detach and disperse to another surface and begin a new cycle of biofilm 
formation.   
 
Figure 2.3: Schematic development of a biofilm in five stages: (1) initial reversible attachment 
of cells onto the surfaces; (2) production of ECM to solid the attachment; (3) early 
development of biofilm structure (microcolony); (4) maturation of biofilm; (5) dispersion of 
free-swimming cells from the biofilm into environment. After stage 5, some of the dispersed 
planktonic bacteria from biofilm to initiate a new cycle of biofilm formation elsewhere. 
Image reproduced from Galanakos et al.46 with permission from Elsevier. 
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Bacteria in biofilms secrete an extracellular polymeric substance (EPS) which is 
adhesive also forms a physical barrier preventing antibiotics and other active agents 
from penetrating.47 The EPS in biofilms as a filter that retain the host-produced serum 
components or minerals.31, 34 It has been reported by Anwar et al.48 that when using 
the same dosage of tobramycin (with drug levels far exceeding the minimum 
inhibitory concentration (MIC)) in the treatment on P. aeruginosa, the reduction of 
P. aeruginosa biofilm cells only reached approximately 2 logs, while there was >8-log 
decrease in planktonic cells. The resistance mechanism is due to the bacteria residing 
in a biofilm.49 Three main mechanisms have been hypothesised:28 slow penetration 
of antibiotics into the biofilm, altered microenvironment within the biofilm, and 
resistant phenotype of the bacteria. As biofilms display a high level of tolerance 
toward antibiotics, bacterial adhesion should be primarily prevented to inhibit 
biofilm formation on devices.50-51 Moreover, once a biofilm forms on a medical 
device, planktonic bacteria can break off a mature biofilm and easily flow into the 
bloodstream or to infect a secondary location.50-51 Whereas these dispersed 
planktonic bacteria can be eradicated through the combination of antimicrobials 
treatment and host immune responses, some highly tolerant biofilm bacteria may 
not be eliminated easily and this can lead to recurrence of infection.52 In most cases, 
once a biofilm forms, replacing the bacterial colonised device or surgically removing 





2.2 Antimicrobial Strategy 
The susceptibility of bacteria to antimicrobials can be measured on bacteria in 
planktonic (free-floating) or biofilm states.54-55 The initial effectiveness of 
antimicrobials is normally evaluated with the planktonic microorganisms.56 However, 
the antimicrobial test on biofilm bacteria are believed to be more appropriate 
because this resembles real world settings more where a higher concentration of 
antibiotics are required in killing the mature biofilms.57 
Bacteria can be classed into two categories: gram-positive and gram-negative 
bacteria; a classification based on the detailed illustration of the membrane structure 
differences between gram-positive and gram-negative bacteria was shown in Figure 
2.4. Cellular machinery of each bacteria is surrounded by protective membranes. 
Gram-positive bacteria have a thicker and more rigid peptidoglycan cell wall outside 
the cytoplasmic membrane, while the gram-negative bacteria is protected by a 
thinner peptidoglycan layer sandwiched between a cytoplasmic membrane and an 
outer membrane. The addition outer membrane provides more permeability barriers 
for gram-negative bacteria, therefore, leading to more antimicrobials resistance.58 
Due to different cell surface characteristics, gram-positive and gram-negative 
bacteria displayed different susceptibility to various antibiotics and antimicrobial 






Figure 2.4: Differences of membrane permeability barriers between gram-positive and gram-
negative bacteria. Image reproduced from Singh et al.58 with permission from Elsevier.  
 
Many strategies are being adapted to eliminate antimicrobial resistance, such as the 
use of new generation antibiotics, combination therapy, antibacterial substances and 
targeted drug delivery, etc. 
2.2.1 Types of Antimicrobials 
2.2.1.1 Natural Compounds 
Natural antimicrobials generally are extracted from natural sources such as animals, 
microorganisms, and plants that use these compounds as a host-pathogen response. 
Examples of these compounds include things like antimicrobial peptides and 
enzymes such as lactoferrin, lysozyme, magainin, nisin lactoperoxidase, chitosan, 
pleurocidin, and spheniscin.59-62 Nisin is an example of a microbial metabolic 
products. It is produced by the bacterium Lactococcus lactis, displayed an effective 
antimicrobial against gram-positive bacteria.63 Plant derived antimicrobial products 
can also include essential oils such as eucalyptus, tea tree, lemongrass, etc.62 The 
antimicrobial activity of essential oils is mainly attributed to the presence of phenolic 
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and terpenoid compounds which sensitise the cell membranes and impair microbial 
enzyme systems 
2.2.1.2 Antibiotics 
Antibiotics are a group of drugs that are used to treat bacterial infections. Since 
Alexander Fleming in 1928 discovered penicillin which is the first antibiotic, antibiotic 
therapy has achieved success against bacterial infections in clinics.64 Development of 
new antibiotics is still one of the antimicrobial strategies to combat resistant 
pathogens and treat bacterial infections. However, the discovery of new antibiotics 
and the approval procedures of the new drugs has been slow in recent years and 
there has been no new class of antibiotic discovered in over 30 years.65 Moreover, 
every class of antibiotics today has bacteria that have developed resistance towards 
it. Antibiotic combination therapy has been designed to improve the limitation of 
monotherapy in response to the problems of AMR. Some of the potentials of 
combination therapy has been reported, including the activity enhancement of 
antibiotics by synergy, prevention of resistance, inhibition the formation of biofilms, 
penetration improvement of antimicrobial agents into cells and tissues, and 
reductive production of toxin.66   
2.2.1.3 Inorganic Bactericides  
Inorganic antimicrobial agents are very attractive alternatives in doped biomaterials. 
They possess many advantages, such as good antimicrobial activity, biocompatibility, 
and adequate stability.67 Silver and its ion form have broad antibacterial spectrum on 
both gram-positive and gram-negative bacteria by interrupting cell membrane 
transport and blocking cell DNA division.68 However, it has been controversial over 
antibacterial silver. As an environment issues, concerns were raised about the 
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toxicity level of silver on organisms in marine ecosystem.69-70   Gold nanoclusters has 
been reported to have wide-spectrum antimicrobial activity when the sizes 
controlled to 2 nm.71 Copper nanoparticles also performed antimicrobial activity by 
destroying the cell wall of bacteria.72  
2.2.1.4 Organic Bactericides 
Synthetic organic antimicrobial agents including chlorhexidine, chloroxylenol, and 
poly(hexamethylene biguanide) are good alternatives if regarding antibiotic 
resistance.73-74 Due to broad spectrum of antimicrobial action and lower risk of drug 
resistance, they are widely used in daily life, especially chlorhexidine. Chlorhexidine 
is known for its wide range of applications in dentistry, such as the combination use 
with gelatine for the treatment of periodontal infection.75 
2.2.2 Modification of Biomaterials to Impart Antimicrobial Activity 
Tethering of antimicrobial agents onto biomaterial has become a primary strategy in 
preventing bacterial-related infections of implanted medical devices in the past few 
decades.76-77 The main strategy used for the development of antimicrobials is to 
prevent the colonisation of a surface before bacteria adhere. This is because once 
the bacteria adhesion to a device surface, biofilms would form on the surface and 
lead to biofilm-related infections, which are difficult to eradicate as described above. 
Therefore, the tailoring of surface modifications depends upon the antimicrobial 
strategies, including bacterial adhesion controlling, bacteria killing, and biofilms 
disrupting.78 There are three main surface modification strategies to controlling 
bacterial adhesion preventing biofilm adhesion: antiadhesive surfaces, contact killing 
surfaces and biocide releasing surfaces.79  
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2.2.2.1 Antiadhesive Surfaces 
Antiadhesive surfaces work on the principle of preventing microbes from sticking to 
the surface by physical rather than chemical means. These surfaces are sometimes 
called non-fouling or antifouling surfaces as the prevent contamination, protein 
adhesion and other routes to promoting the early phase of bacterial adhesion on 
surfaces. Surface contamination or proteins that adhere onto a surface can promote 
the adhesion of bacteria and the formation of biofilms.80-81 Various surface 
modification techniques have been used in this regard such as polymer brush 
coatings,82 self-assembled monolayers83 and micro/nano structure, are carried out 
to develop these antiadhesive inert surfaces. Ge et al.84 has fabricated micro/nano 
pillar arrays on a Si substrate, and the pillar patterns with a sub-micrometre level 
performed large reduction on bacterial retention and growth. Yang et al.85 has 
developed another micro pattern which is called honeycomb-like structure. The 
fabricated honeycomb-like patterns with feature sizes of 1 µm notably inhibit 
bacterial adhesion, growth and biofilm formation against E. coli and S. aureus.  
The antiadhesion on some charged surfaces performed by electrostatically 
interaction with ECM.86 Superhydrophobic surfaces also act as antiadhesive surfaces 
and has been widely used for antifouling applications.     
2.2.2.2 Contact Killing Surfaces 
There are a broad range of antimicrobial molecules that possess antibiofilm activity 
have been introduced into coatings or been grafted onto surfaces.87 These coatings 
that contain antimicrobials, such as antimicrobial peptides and quaternary amines, 
do not release bactericides, but killing bacteria on contact are the second strategy to 
develop on antimicrobial surfaces.88-89 They work with different mechanisms:87 
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selectively degrading ECM of biofilms, killing metabolically quiescent bacteria within 
biofilms, disrupting Quorum sensing system, and reducing biofilm metabolism. The 
combination of different molecules has been proved to enhance the antibiofilm 
efficacy.90 Furthermore, the biofilm treatment of antibiotics associated with the 
antibiofilm molecules also displayed the similar result in biofilm killing.91 The 
advantage here of these coatings is that it can kill bacteria on contact without 
leaching into the environment. The disadvantage is that it has more of a localised 
effect.   
Antimicrobial coatings on bulk materials aim to provide antimicrobial activity in 
biomaterial-tissue interface without compromising the mechanical property and 
biocompatibility of the bulk materials. However, some coating strategy would 
weaken the function of the host tissue by performing cytotoxicity or causing negative 
immune response. Therefore, it is of notable importance to balance the antimicrobial 
property and the biocompatibility in designing the coating.  
2.2.2.3 Biocide Leaching Surfaces 
Several bioactive antimicrobial coatings are based on leaching the active agent into 
the vicinity of the surface. These include releasing active antimicrobial such as 
reactive oxygen species,92-93 nitric oxide,94 thin films with organic/inorganic 
antimicrobials.95 The advantage of these coating is that bacteria do not need to come 
into the surface of the material in order for the bactericidal application, however 
there might be a problem with leaching and toxicity of the material in the 




2.3 Nitric Oxide 
2.3.1 Nitric Oxide (NO) Molecule 
Nitric oxide is a biological signal molecule that regulate cellular metabolic functions 
in physiological condition.96-97 As an endogenously produced diatomic free radical 
with a short half-life (< 1 s in the presence of oxygen and haemoglobin), NO is 
associated with multiple physiological processes, including blood pressure 
regulation,98 wound healing,99 immune response100-101 and skeletal homeostasis.102-
103 Endogenous NO is enzymatically produced from ι-arginine by NO synthase 
(NOS).104 NOS possesses three isoforms, including endothelia NOS (eNOS), inducible 
NOS (iNOS) and neuronal NOS (nNOS).105 Low concentrations (10-12 – 10-9 M) of NO 
that promote vasodilation, angiogenesis and neurotransmission, are produced by 
eNOS and nNOS.105 Larger concentrations (10-6 M) of NO that response to infections 
and inflammations, are produced in macrophages and neutrophils by iNOS.105 NO will 
be oxidised by superoxide (O2•-) to form peroxynitrite (ONOO-) which is a more 
powerful oxidant in response to inflammatory.94 
2.3.2 NO as an Antimicrobial and Antibiofilm Agent 
The intrinsic broad-spectrum activity of NO against microorganisms is attributed to 
its reactive byproducts that produced through the spontaneous reaction of NO with 
oxygen or superoxide.106-107 The nitrosation and oxidation of reactive nitrogen oxide 
species (RNOS) (i.e. nitrogen and oxygen intermediates) can cause nitrosative and 
oxidative damage to bacterial DNA, proteins, metabolic enzymes, and outer 
membrane structure.108 The antimicrobial mechanisms are illuminated in Figure 2.5. 
Nitrosative species, such as dinitrogen trioxide (N2O3), that induce DNA deamination 
and thiols nitrosation cause bacterial death.106, 109 Oxidative species, such as 
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peroxynitrite (ONOO-) which is formed by NO reacting with superoxide, perform 
oxidative DNA damage and lipid peroxidation of pathogen cells.109  
 
Figure 2.5: (A) Antimicrobial mechanisms of NO which acts as an antimicrobial agent. (B) 
AFM image of NO-treated bacteria. (C) The control group of bacteria. Images reproduced 
from Carpenter et al.110 with permission from Royal Society of Chemistry.   
 
Due to the small size of NO molecule and its multiple mechanisms in eradicating 
pathogens, there has been no reports of bacteria developing resistance to NO.111 The 
antibacterial efficacy of NO has been shown to be capability of broad-spectrum 
antibacterial against gram-negative (e.g., P. aeruginosa and E. coli) and gram-positive 
(e.g., S. aureus and S. epidermidis) bacterial species, even drug-resistant bacteria 
(e.g., methicillin-resistant S. aureus).112-113 Miller et al.113 has intermittently exposed 
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drug-resistant strains of E. coli and S. aureus to gaseous NO (160-200 ppm for 30 min 
every 4 h) for one day in vitro. This protocol eradicated the drug-resistant bacteria 
without causing significant cytotoxicity. Similar results also can be seen in treating 
planktonic P. aeruginosa in vivo.114 
Moreover, the study of antibiofilm activity of NO attracted a lot interest in recent 
years.115-116 It has been illuminated in Section 2.1.2 that the final dispersal stage in 
biofilm formation plays a key role in further colonisation and widespread the biofilm 
infection. NO acts as a signalling molecule in regulating the formation and dispersal 
of biofilms at a low NO levels of pico/nano molar concentration.115 The detachment 
of P. aeruginosa from a mature biofilm has been triggered at NO concentration of 
0.025-0.5 nM over 24 h.116 The same NO donors also has been used in investigating 
a wider range of pathogenic biofilm dispersal. It has been concluded that low levels 
of NO possess capability of causing 30-90% biofilm dispersal without reducing its 
viability. Bacteria that dispersed from biofilm and transform back to a planktonic 
state via NO treatment normally displayed higher susceptibility to antimicrobial 
agents.117-118 When using antimicrobials (tobramycin and hydrogen peroxide) for 
biofilm treatment, the addition of NO exposure performed 2-log higher reduction.118 
Although the low levels of NO performed no effects on viability reduction of biofilms, 
it significantly increased the susceptibility of biofilms to antimicrobials by dispersing 
biofilms and rising the susceptibility of planktonic bacteria.117-118 High levels of NO 
concentration (micros/milis molar concentration) have completely eradicated 
biofilms in a previous research.119 While the high concentration NO-mediated biofilm 
eradication has not been fully studied, one acceptable understanding is that the 
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physical destruction of biofilms associate to the altering of the EPS matrix by NO.120-
121   
2.3.3 Role of Nitric Oxide in Bone Tissue 
Bone is a dynamic tissue that constantly undergoes remodelling.122 Osteoblasts 
deposit new bone, while osteoclasts remove mineralised bone and organic tissue. 
Balanced activity of osteoblasts and osteoclasts is of great importance in maintaining 
bone function. For example, the reduced activity of osteoclast contributes to 
osteopetrosis, while the excessed osteoclastic activity can amplify bone loss.  
Endogenous NO molecule has been found get involved in signalling pathways 
controlling bone cell physiology and bone remodelling.123-126 Increased activity of the 
three NOS isoforms has been detected in bone fracture sites in human and rats.127-
128 nNOS and eNOS are calcium-dependent and constitutively expressed in human 
primary osteoblasts. iNOS is calcium-independent and iNOS-derived NO showed the 
capacity of activating osteoclasts in bone inflammatory process, which promotes the 
bone remodelling.129 The production of NO enhanced osteoblastic proliferation and 
differentiation, promoting bone deposition.130 A decreased eNOS-derived NO level 
has been shown to increase osteoclastogenesis and related bone resorption.131  
Mechanical strain on bone without causing fractures also stimulates NO production 
by osteoblasts for bone functional recovery.132 In this case, activity of osteoclasts has 




2.3.4 Role of Exogenous Nitric Oxide on Bone Cells 
Endogenous NO is involved in bone repair process, therefore, NO concentration 
levels on regulating bone physiology should be taken into consideration in delivery 
strategy of exogenous NO.   
To determine whether gaseous NO performs the same function on simulating bone 
cell growth as endogenous NO, S-nitroso-N-acetylpenicillamine (SNAP, a NO donor) 
has been used in osteoblast culture.133 With the addition of SNAP, levels of alkaline 
phosphatase and cell numbers in osteoblasts have both increased, giving the promise 
of NO as a therapeutic for bone growth. Otsuka et al.133 used 
diethylenetriamine/nitric oxide (DETA/NO) to incubate with osteoblasts and found 
no change in alkaline phosphatase level. However, a 3.5-fold increase in osteocalcin 
has been measured. Osteocalcin is an osteoblastic protein that promote the 
mineralisation of bone matrix. Furthermore, the NO releasing rate significantly 
impacted the local concentration of NO. To understand the NO releasing rate in 
regulating osteoblast behaviours, hence, slow release of NO from eNOS was 
modelled by DETA/NO while rapid release of NO from iNOS was mimicked by sodium 
nitroprusside (SNP).134 At a low levels of donor concentration (10 µM), both DETA/NO 
and SNP displayed enhancement on osteoblasts proliferation. At a higher 
concentration (50 µM), osteoblasts performed proliferation on DETA/NO and 
apoptosis on SNP. Once the donor concentration increased to 100 µM, both 
DETA/NO and SNP displayed cytotoxicity on osteoblasts. It has been indicated that 




Effects of exogenous NO on osteoclasts dependent upon the NO release kinetics, 
including NO donor concentration and release duration, etc..135 And elevated levels 
of NO have been found to cause osteoclastic apoptosis and inhibit 
osteoclastogenesis. Kanaoka et al.136 has reported that bone stromal cells performed 
high osteoprotegerin (OPG), when supplemented with 15 µM DETA/NO, resulting in 





2.4 NO Donors 
2.4.1 Classes of NO Donors 
NO has efficacy in antibacterial and antibiofilm, the delivery of exogenous NO is often 
therapeutically difficult because NO is a reactive gas with a short half-life. As a result, 
much research has focused on the development of NO donors capable of controlled 
and sustained release in the therapeutic window. There are four common NO donors 
that have shown are commonly used: N-diazeniumdiolates, S-nitrosothiols, organic 
nitrates and metal nitrosyl.  
N-diazeniumdiolates (containing [N(O)=NO]-) are the NO adducts of precursor 
amines (Figure 2.6). The first N-diazeniumdiolates were reported by Drago in 1960, 
which involves the reaction of NO with selected nucleophiles.137-138 The synthesis of 
N-diazeniumdiolates under high NO pressure was later refined by Keefer and 
coworkers.139-140 N-diazeniumdiolates can form on both primary and secondary 
amines after NO treatment. Most of the studies focused on secondary amine N-
diazeniumdiolates because if its higher stability.139 N-diazeniumdiolates are formed 
by deprotonating secondary amines using a base such as sodium methoxide or 
sodium hydroxide.138 The amine anion then nucleophilically attacks 2 molecules of 
NO and form the N-diazeniumdiolate moiety. Under physiological conditions, N-
diazeniumdiolates spontaneously release two molecules of NO per.138, 141 The 
mechanism diagram of N-diazeniumdiolates formation and NO release is shown in 
Figure 2.6. The kinetics of release of N-diazeniumdiolates can be controlled by pH or 
temperature dependent process.142 For example, N-diazeniumdiolate-modified 
proline (PROLI/NO) displayed a NO-release half-life of 2s while N-diazeniumdiolate-
modified diethylenetriamine (DETA/NO) for 24 h.143 The terminal primary amines on 
25 
 
DETA are believed to stabilise N-diazeniumdiolate by forming intermolecular rings, 
therefore, allowing down the degradation rate and NO release. This class of NO 
donor is the most widely exploited for medical applications and indeed used in this 
thesis as the kinetics and payload of NO can be carefully controlled.   
 
 
Figure 2.6: Mechanism diagram of N-diazeniumdiolates formation and degradation.  
 
S-nitrosothiols are endogenous NO carriers. They are synthesised via nitrosation of 
free thiols with nitrosating agents.144 NO release from S-nitrosothiols is also a 
spontaneous process. Some of the commonly used S-nitrosothiols include S-
nitrosoglutathione (GSNO) and SNAP. Organic nitrates have been the oldest NO 
donors in clinical use.145 However, some potential shortcomings of organic nitrates 
have been found in clinical applications. For example, nitroglycerin, the most used 
organic nitrate, efficiently release NO after being active. But patients often develop 
tolerances to nitroglycerin and can limit NO release capacity of nitroglycerin, 
resulting in low treatment efficacy.146 Metal nitrosyl compounds are a family of 
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coordination complex containing NO ligands. SNP is the most common in metal 
nitrosyl class145 and it has been used for treating high blood pressure.147 Some 




Table 2.2: Common nitric oxide donors.  
Donor type Chemical 
formula 




N-diazeniumdiolate R2NN(O)NO PROLI/NO Proton-initiated decomposition 1.8 s148 pH 7.4, 37°C 
DETA/NO 20 h148 pH 7.4, 37°C 
S-nitrosothiol RSNO SNAP Photolysis 1.7 h149 pH 7.4, 37°C, in dark 
Thermal decomposition 
Cu(I)-catalysed reduction 
Organic nitrate RONO2 Nitroglycerin Enzymatic decomposition N/Aa  
Metal nitrosyl Varies SNP Photolysis N/Aa  




2.4.2 Comparison of NO Donors for Antimicrobial Applications  
Each NO donor class presents its own NO loading mechanism and certain advantages 
for NO release. Based on the NO release mechanisms of the donors, the efficacy of 
each donor class on treating bacterial and biofilm related infections need to be 
evaluated. Organic nitrates require enzymatic activation and this hinders their utility 
for antimicrobial applications. Also the enzymes that present in surrounding tissue 
may deactivate the NO release from organic nitrites.150 Metal nitrosyls, such as SNP, 
are photolytic NO donors; i.e. an external light trigger (e.g. UV or visible light) is 
needed for the release of NO release profile of metal nitrosyls, limiting its utility for 
implanted biomaterials. Additionally, metal nitrosyls have storage challenges owing 
to their light sensitivity. In addition, the toxicity of metal centres and ligands on tissue 
cells need to be considered in applications. Although S-nitrosothiols are used as NO 
donors for killing bacteria,151 their decomposition is easily triggered by temperature, 
light, the presence of transition metal ions (e.g. copper) and the other thiols, hence 
resulting in relative instability.152-153  
N-diazeniumdiolate spontaneously decomposition under physiological conditions to 
generate 2 molecules of NO. N-diazeniumdiolates generally need to be stored under 
in low temperature and moisture-free conditions to prevent its degradation. The NO-
release kinetics and stability of N-diazeniumdiolates have been improved via 
modifications with other chemical structure.154-155 The cytotoxicity of N-
diazeniumdiolates precursors is of concern, aminosilane precursors have been used 
to tune antimicrobial efficacy towards bacteria and cytotoxicity to human primary 
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osteoblasts.156 Therefore, N-diazeniumdiolates promise the most extensive usage for 





2.5 N-Diazeniumdiolate Delivery Vehicles  
Many low molecular weight N-diazeniumdiolates have limitations (e.g. short half-life 
and precursor cytotoxicity), hindering their broader antimicrobial applications.143 N-
diazeniumdiolates delivery vehicles have been developed to address these problems 
as listed below.   
2.5.1 Inorganic Nanoparticles 
Silica nanoparticles have been employed for NO storage and delivery due to its ease 
of synthesis, tuneable structure and nontoxic nature.157 NO donor precursors (e.g. 
secondary amines or thiols organic functional groups) have been introduced onto 
silica nanoparticles for subsequent grafting of the NO donor.158-159 Zhang et al.160 has 
synthesised NO-releasing fumed silica particles (with size of 0.2-0.3 µm) followed by 
tethering alkylamines onto the silica surfaces, and functionalisation with an N-
diazeniumdiolate moiety. Shin et al.157 has reported a one-pot sol-gel method upon 
preparing NO-releasing nanoparticles that with the N-diazeniumdiolates distributed 
uniformly throughout the particles.  
Gold nanoparticles and quantum dots have also been used as delivery vehicles for N-
diazeniumdiolates.112, 161-162 For example, Polizzi et al.161 synthesised N-
diazeniumdiolates-functionalised gold clusters (~3 nm) with modest NO-release for 
short durations (< 0.023 µmol, <1.5 h). These gold clusters (~5 nm) significantly 




2.5.2 Biopolymeric Scaffolds 
Biopolymers widely attract attention in fabricating tissue scaffolds due to their 
favourable nontoxicity, inherent biodegradability and biocompatibility. Chitosan, 
alginate, cyclodextrins and hyaluronic acid have been successfully modified with N-
diazeniumdiolates.163-166 Ahonen et al.166 reported on the synthesis of NO release 
alginate scaffolds of different molecular weights. Those scaffolds demonstrated 
pathogen and biofilm eradication efficiency without causing toxicity towards human 
respiratory epithelial cells. Lu et al.167 have reported on secondary amine 
functionalised chitosan oligosaccharides with varying molecular weights. The 
antimicrobial efficacy was determined to be a function of the size and ionic 
characteristic, with low molecular weight and cationic oligosaccharides showing a 5-
log reduction in P. aeruginosa biofilms. 
2.5.3 Dendrimers 
Dendrimers are an interesting vehicle for NO delivery due to their hyper-branched 
nanostructures which allows for a high NO loading capability.142 Schoenfisch and 
coworkers have shown that NO-functionalised poly(propyleneimine) (PPI) 
dendrimers demonstrated antibacterial activity against gram-positive and gram-
negative bacteria including methicillin-resistant S. aureus. The antibacterial efficacy 
was correlated to the dendrimer size and exterior functionality with minimal 
cytotoxicity towards fibroblast cells with up to a 5-log reduction in all bacterial strains 




2.5.4 Liposomes  
Liposomes are colloidal nanocarriers with a cell membrane-like structure that 
consisted of an inner aqueous core and a phospholipid bilayer outer shell. The 
encapsulation of NO donors into liposomes has been investigated as a strategy for 
NO storage and delivery.169 The NO release kinetics of N-diazeniumdiolates 
encapsulated liposomes upon has been reported to be tuneable via altering NO 
donor molecular structure and/or phospholipid composition.170 The hydrophobic 
phospholipid acted as a physical barrier which has been shown to slow down proton-
initiated degradation rate of encapsulated N-diazeniumdiolates, therefore, 
enhancing the stability of this NO delivery vehicle. 
2.5.5 NO Release Coatings 
For some medical device applications, the development of a coating or thin film on 
an implantable device is the best solution to the reduction of biofilm-associated 
infections.171-173 Three representative strategies for constructing N-
diazeniumdiolates-functionalised surfaces, including noncovalent incorporating, 







Figure 2.7: Representative strategies for constructing N-diazeniumdiolates-functionalised 
surfaces: (A) noncovalent incorporating of NO donors (small blue spheres); (B) covalent 
tethering of NO donors; (C) doping of NO-releasing macromolecular scaffolds (large blue 
spheres). Image reproduced from Riccio et al.174 with permission from Royal Society of 
Chemistry. 
 
Smith et al.175 have fabricated NO-releasing thin film polymers by noncovalently 
doped N-diazeniumdiolated DETA within polycaprolactone (PCL), and detected NO 
release rate of 56 nmol/mg over 1 week. Covalent tethering of N-diazeniumdiolates 
into coatings have been reported by several groups.175-176 For example, D’Sa group 
has reported on the ability of NO-releasing polymer coatings to prevent P. 
aeruginosa biofilm formation.141 Poly (ethylene terephthalate) and silicone 
elastomer were oxygen plasma treated followed by diazeniumdiolate 
functionalisation and these coating demonstrated a 60–92% reduction in viable 
gram-positive and gram-negative bacteria. 
Another approach that can be utilised to generate NO-releasing surfaces was 
proposed by Kumar and coworkers.177 In their work, a solvent-free technique has 
been suggested to generate NO-releasing plasma polymer coatings using 
diazeniumdiolate. The amine-based coatings were deposited using plasma 
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polymerisation followed by NO gas exposure which resulted in a diazeniumdiolate-
functionalised substrate. This coating demonstrated a controlled release of NO for 
over 2 days and was effective at preventing the formation of P. aeruginosa and S. 
aureus biofilms. Recent studies have evaluated the macromolecular scaffold doping 
strategy for NO storage and delivery from the coating. For example, Zhang and 
coworkers160 prepared NO-releasing coating by doping 20 wt% pendant hexane 
diamine structure (i.e., Sil-2N[6]-N2O2Na ) silica particles into polyurethane (PU) 
layer. Koh et al.178 fabricated hybrid sol-gel/PU glucose biosensors which made up of 
two layers, including glucose oxidase and N-diazeniumdiolated silica particle doped 
layer. They reported NO release durations were associated to both the type and 





2.6 Biomaterials for Bone Healing and Regeneration 
Guided bone regeneration (GBR) is a therapeutic method to repair bone defects or 
injuries. The basic principle of GBR method is to isolate the bone defect from the 
surrounding tissue.179 A illustration of GBR for bone defect recovery is shown in 
Figure 2.8.  
 
 
Figure 2.8: Illustration of GBR for bone defect recovery. Image reproduced from Bottino et 
al.180 with permission from Elsevier. 
 
GBR membranes act as barriers in treatment as well as encourage bone 
regeneration.181 Normally, they are used as a medical device with dental implants182 
or bone grafting materials.183 Therefore, the main design criteria of GBR membranes 
including biocompatibility, space maintaining, selective permeability, tissue 
integration and clinical manageability.184 Several factors should be taken into 
consideration when selecting or manufacturing biomaterials for GBR, including 
biocompatibility, osseointegration and mechanical properties and biodegradability, 
wear resistance, etc..185 A material with good biocompatibility will have low 
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cytotoxicity and not cause any inflammatory or allergic response in the human 
body.186 The osseointegration inability of the material will cause implant loosening 
after surgery, resulting in implant failure and revision surgery.187 The mechanical 
properties (e.g. hardness, tensile strength, modulus and elongation) determine the 
type of material that will be employed for a specific application.185 GBR membranes 
can be grouped as non-resorbable or resorbable membranes in terms of specific area 
utility. Non-resorbable membranes, including polytetrafluoroethylene (PTFE) and 
titanium mesh, are capable of maintaining membrane shape for a sufficient 
period.188 However, the drawback of this type is the need of a removal surgery. The 
use of resorbable membranes have avoid this shortcoming. A variety of natural or 
synthetic polymers, such as collagen and aliphatic polyesters, are used in fabricating 
resorbable membranes.189         
2.6.1 Titanium Implants 
2.6.1.1 Surface Structure and Properties of Titanium  
Titanium (Ti) is a metal, first discovered in England by Gregor in 1790 and named by 
Klaproth in 1795. And its alloys have been used extensively as an orthopaedic and 
dental biomaterial due to its good biocompatibility, osteointegration, and suitable 
mechanical and corrosion resistance. Many of its favourable properties is associated 
to the presence of the surface oxide layer. A native titanium oxide film with only a 
few nanometres thick grows spontaneously on Ti surface upon exposure to air.190 In 
detail, the amorphous or nanocrystalline oxide film with a thickness of 3-7 nm mainly 
contains stable TiO2. A hydroxyl layer (i.e. physiosorbed water layer) is formed via 
hydroxide and chemisorbed water bond with Ti cations. In addition, to avoid a 
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contamination layer that can attach onto surface, Ti should be stored in clean 
condition. A diagram of titanium oxide film is illustrated in Figure 2.9.   
 
 
Figure 2.9: Illustration of titanium oxide film. Image reproduced from Liu et al.191 with 
permission from Elsevier. 
 
2.6.1.2 Ti Surface Enhancement by Silanisation  
Surface modifications on Ti surfaces are known to improve cellular adhesion, 
differentiation and other cell-tissue response without adversely affect the bulk 
properties. The main strategies of surface modification include immobilisation of 
peptides, proteins or growth factors onto Ti surfaces.192-193 A number of techniques 
(e.g. self-assembled monolayers, protein immobilisation) have been developed for Ti 
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surface modification.194-195 However, as a result of existence of the inert TiO2 layer, 
any modification needs to take place with this oxide layer. Aminosiliane, a strong 
coupling agent, is one of the a few available organic reagents that can form strong 
chemical bonds on TiO2 layer.196 In addition, silanised surface has achieved stability 
and wear resistant in clinical application.197  
The formula of aminosilane is represented as  
R-Si(OR’)3, 
where OR’ is the hydrolysable alkoxy group, and R is the backbone with amino-
functional group(s).  
At the initial stage of silanisation on Ti surface, the aminosilane is activated by 
hydrolysed 
R-Si(OR’)3 + 3H2O → R-Si(OH)3 + 3R’-OH                                                              (1) 
The reaction can be triggered by water molecules.  
With the increase of the acidic silanol groups (-SiOH) in the solution, dimers are 
forming 
R-Si(OH)3 + R-Si(OH)3 → R-Si(OH)2-O-Si-(R) (OH)2 + H2O                                   (2) 
Titanium surface with a thin oxide layer possesses hydroxyl groups (-OH), therefore, 
enabling the formation of ≡Si-O-Ti≡ bonds.198 Usually only one siloxane bone from 
each silicon atom link onto the inorganic substrate.199 Heat treatment is the final step 
in silanisation, thermal curing has been reported to enhance the crosslinking of 
aminosilanes to form a siloxane film onto metal surfaces through eliminating H2O.200  
39 
 
Since most silanes do not dissolve in water, ethanol (~90-95% vt%), this is an effective 
surface modification technique that has been a viable solution in clinic.201   
There are several factors that affect the quality and stability of formed aminosilane 
layer on Ti surfaces, such as functionality of the amine to the silicon centre, type of 
the alkoxy group, and concentration of silanes.202-204 Here, we only consider the case 
of single species aminosilane utility in surface silanisation.  
a. The amine group is able to, both inter- and intramolecularly, catalyse the 
formation and hydrolysis of siloxane bonds. The intramolecular catalysis is 
achieved via the formation of a stable five-membered ring intermediate.205   
b. The two alkoxy groups, methoxy group and ethoxy group, have different 
hydrolysis rates. The faster hydrolysis rate of methoxy groups results in a high 
variability of the silane layer, because the layer structure is more susceptible 
to the amount of water on substrate surfaces.203 
c. The hydrophobic polysiloxane film is not a simple monolayer but usually with 
a thickness of ten molecular layers. The thickness of the film dependent upon 
the concentration of the silane solution but not the reaction time.204   
2.6.1.3 Porous Titanium 
While titanium and its alloys are widely employed in the orthopaedic and dental 
sector, dense forms of these materials can cause a mismatch of the Young's modulus 
leading to stress‐shielding and poor interfacial connectivity between the bone and 
implant. Consequently, this can lead to fibrous tissue formation at the implant 
interface, poor osseointegration and the development of an inflammatory response. 
Porous titanium can avoid some of these issues such as decrease in Young’s modulus 
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(in comparison to bulk metals) that will match bone more. This will prevent stress 
shielding which can lead to bone resorption and implant loosening. The porous 
structure facilitate the migration of cells, effective transport of body fluids, and 
integration of newly grown bone.206-208 It is generally accepted that a high porosity 
of interconnected pores which can allow for cell migration and growth and 
vascularisation should have pore sizes in the range of 100–400 µm. Given the 
importance of porosities in metallic biomaterials, researchers have investigated 
fabrication of porous titanium such as plasma spraying, additive manufacturing, 
furnace sintering, lost wax casting and vapor deposition has been used to 
manufacture porous titanium.209-210 The lost carbonate sintering which is one of the 
sintering manufacturing processes has been developed and patented by Zhao et 
al..211 It has been widely used for applications in energy, aerospace and civil 
engineering.212-215    
2.6.2 Degradable Polymeric Scaffolds for Bone Regeneration 
Several techniques have been used for degradable polymeric scaffolds for including 
film casting, dynamic filtration and electrospinning.180, 216-219 Membranes made by 
film casting and dynamic filtration methods have been found lack of clinical 
manageability and component uniform.   
2.6.2.1 Electrospinning  
Electrospinning is a simple and economical method used for effectively fabricating 
continuous micro-/nano- fibres from a variety of polymer solutions.220-223 Although, 
this technique was first developed over 100 years,224 its widespread application in 




A typical electrospinning setup (as shown in Figure2.10a) consists of four following 
components:  
a. High-voltage power supply: a direct current (DC) voltage in the range of 
several tens of kVs is applied to the system, and build up a surface charge on 
the polymer solution.225      
b. Flow control pump: a flow control pump is used to adjust the flow rate of the 
fluid in the system, in order to generate fibres with controllable diameters.221   
c. A capillary tube with a needle: when electrostatic repulsion force of surface 
charges overcome surface tension, the polymer droplet can be stretched into 
a conical shape known as the Taylor cone at the needle tip. The Taylor cone 
will be invisible, and fibres formation starts within the needle if the applied 
voltage is high enough.226 The formation of Taylor cone is shown in Figure 
2.10b.  
d. A collector: For different fibre assemblies, collectors can be designed in 






Figure 2.10: Illustrations of (a) typical electrospinning set-up and (b) the effect of voltage on 
Taylor cone formation. Image reproduced and adapted from Islam et al.222 with permission 
from Springer.  
 
Polymers are dissolved in volatile solvent before electrospinning. In the 
electrospinning process, the polymer solution is held at the needle tip by surface 
tension. Once the repulsive electrical force increases to a value sufficient to 
overcome the surface tension, the polymer droplet is stretched to form a conical 
shape called Taylor cone.227 The charged cone then pulls into a charged jet of polymer 
solution, and then the jet rapidly and unstably whips between needle tip and 
collector to achieve evaporation of the solvent. Eventually, the polymer fibres are 
left behind onto collector.223, 228-229   
The electrospinning process is governed by many parameters, those are summarised 






Table 2.3: Electrospinning parameters and their effects on fibres morphology. 
Class of parameter Parameters  Effects on fibres Ref.  
Electrospinning 
processing  
Voltage Decrease in fibres diameter with increase of voltage. 230 
Flow rate Increase in fibres diameter with increase of flow rate; 
Generation of beads with too high flow rate. 
228, 231 
Types of collector Generation of beaded fibres on less/no conducting material collector; 
Generation of aligned fibres on rotating collector with alignment speed.  
232-233 
Distance between needle tip and 
collector 
Decrease in fibres diameter with increase in distance; 




Viscosity  Increase in fibre diameter with increase of viscosity; 
Generation of beads in low viscosity.  
235-236 
Concentration Increase in fibre diameter with increase of concentration. 237-238 
Molecular weight of polymer Increase in beads amount with decrease in molecular weight. 239-240 
Conductivity  Decrease in fibre diameter with increase in conductivity. 241-242 
Ambient  Temperature  Decrease in fibres diameter with increase in temperature. 243 






The morphology and arrangement of fibres are controllable in an electrospinning 
fabrication. In addition, there are a wide range of polymers can be selected to use 
for this easy-setup and low-cost processing.245 A unique character of electrospinning 
is that a large one-piece membrane can be fabricated at one time.246 As GBR 
membranes are usually used in small pieces, the repeatability of membranes can be 
achieved by electrospinning. Electrospinning has greater potential in fabricating 
degradable GBR membranes out of a variety of polymers and can act effectively as 
vehicles for drug delivery applications. Hatton and coworkers have developed 
electrospun poly (ε-caprolactone) (PCL) membranes with bioactive glass composition 
(F18). These membranes displayed increased tensile strength with the addition of the 
bioactive glass and not cytotoxic and therefore showed promise as GBR membranes 
for small bone injuries.247 Moreover, electrospun membranes also are versatile and 
have been used with dual functionality for tissue regeneration and drug delivery. For 
example, Colley et al.248 have reported on the fabrication of an electrospun dual-
layer mucoadhesive electrospun scaffold which consists of an outer 
hydrophobic polycaprolactone layer and an inner, mucoadhesive 
polyvinylpyrrolidone (PVP) and Eudragit® RS100, layer. These patches were effective 
in sticking to mucosal tissue without cytotoxicity and were successfully loaded with 
drugs for the treatment of oral lesions. Clitherow et al.249 have demonstrated that 
PCL and PVP/RS100 (PVP/RS100) electrospun patches are effective antifungal drug 






This literature review chapter provides a detailed background for the study and 
design of antimicrobial biomaterials for bone tissue engineering in this thesis. The 
strategy used in this thesis for addressing implant biofilm associated orthopaedics 
infections is to exploit the antimicrobial function of NO without using antibiotics 
which lead to drug resistant bacteria. As NO is a reactive gas molecule and has short 
half-life, the chemical properties and delivery mechanisms (e.g. coatings, scaffolds) 
of NO donors (mainly N-diazeniumdiolates) have been reviewed in this chapter. Two 
main types of biomaterials that are used to fabricated orthopaedic implants are also, 
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Chapter 3: Nitric Oxide Releasing Titanium Surfaces for 
Antimicrobial Bone-Integrating Orthopaedic Implants* 
3.1 Introduction 
Implant-associated infections represent a serious complication as once bacteria 
colonise the surface, they form biofilms, which are more difficult to treat, requiring 
up to a 1000-fold increase in the antimicrobial dose.8, 250-251 Once an infection takes 
place on a titanium implant, repeated revision surgeries are often required and can 
lead to poor implant integration, bone loss and soft tissue defects.252-253 Orthopedic 
implant infections are caused most often caused by Staphylococcus species (S. aureus 
and S. epidermidis) or Pseudomonas aeruginosa which can be acquired during 
surgery or subsequently through a hematogenous route.3, 254 Moreover, implants 
that are transmucosal and percutaneous (e.g. dental and external fixation pins) are 
more susceptible to infection as opportunistic bacteria that reside on the skin 
mucosa can colonise the peri-implant soft tissue which can lead to a peri-implant 
bone infection.255-256 Localised delivery of antibiotics via a coating layer on the 
implant is seen as a promising strategy to prevent infections and subsequent failure 
of the implant. However, given the rise in the global epidemic of antimicrobial 
resistance, much focus has changed to the development of alternative antimicrobials 
such as silver,257-258 zinc ions,259 bioactive antibodies,260 antimicrobial peptides261-262 
and nitric oxide36, 111 which have a low tendency to developing multi drug resistant 
bacteria.  
Nitric oxide (NO) is a potent broad spectrum antimicrobial and part of the body’s 
defense mechanism that is activated by inflammatory cells (neutrophils and 
macrophages) which are responding to invading pathogens such as bacteria, 
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protozoa and fungi.116, 263 The antimicrobial activity of NO is attributed to the reactive 
nitrogen oxide species (RNOS) that are produced through the spontaneous reaction 
of NO with oxygen or superoxide that cause damage to bacterial DNA, proteins and 
lipid membranes.106-107 The formation of these RNOS become significant or 
antimicrobial when the concentration of NO is >1μM.106 Given that there are several 
mechanistic pathways for NO to inactivate bacteria, studies have shown that there is 
a low tendency for bacteria to develop resistance to this antimicrobial.108, 121 
Furthermore as eukaryotic cells have evolved mechanisms that are capable of 
scavenging these RNOS, it is thought that NO will exhibit a low toxicity on the host.263  
Although NO is clearly identified as a potent antimicrobial, its clinical utility is 
challenging as NO is a highly reactive gas with a short half-life.264 As such, there has 
been much research focused on the development of NO donors such as N-
diazeniumdiolates, S-nitrosothiols, organic nitrates, metal nitrosyls which can store 
and release NO for more prolonged periods of time under requisite conditions.145, 148, 
265 The most commonly reported N-diazeniumdiolates (containing the [N(O)=NO]-) 
are adducts formed from a NO dimer with a secondary amine nucleophile.148, 264 
These N-diazeniumdiolates can spontaneously decompose with tunable half-lives 
dependent on the structure of the nucleophile (amine), pH and temperature.148 As 
secondary amine diazeniumdiolates are formed much easier, much work has focused 
on these rather than primary amine diazeniumdiolates.177, 266-268 Although many of 
these studies have investigated how NO can be released for biomaterial/medical 
device applications, there is a paucity of information regarding the mechanism of 
release and the robustness of the coatings. For example, Ho and coworkers177 
focused on the feasibility of using plasma polymerisation to coat polymer surfaces 
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with allylamine and diallylamine coatings, followed by the incorporation of 
diazeniumdiolates. In this study, although they have looked at primary and secondary 
diazeniumdiolates and have obtained a higher NO payload with the secondary 
diazeniumdiolate, they have not evaluated the stability or shelf-life of the coatings 
or investigated the potential cytotoxicity of the materials. Moreover, the underlying 
coatings are not optimised to promote osseointegration.  
Amino terminated silanes (as opposed to methyl, hydroxyl, or thiol) have been found 
to control cell responses, resulting in the formation of high quality de novo tissue.269-
270 These comprehensive investigations were performed with a variety of silanised 
glass surfaces to understand the effect of silane chain length on associated 
osteoinductive properties of the surface.269 Within this chapter, only the longer chain 
silanes containing pendant amino groups resulted in the formation of an apatite‐like 
layer on the surface that induced a significantly enhanced osteoinductive response 
across the entirety of the surface.  
Therefore, amino-terminated silane (11‐Aminoundecyltriethoxysilane, AUTES) with 
the most consistent and homogeneous osteoinductive property has been selected 
and used to tether NO. The hypothesis here is as the underlying surface is known to 
be osteoinductive, once the NO is released and any potential infection during 
implantation is averted, osseointegration can take place. Within this preliminary 
study we investigate the effect of NO on the initial and prolonged (after 7 days) viable 
adhesion of primary human osteoblasts to the modified surfaces. However, since 
primary diazeniumdiolates are not as well studied and do not release as much NO,137 
another potentially osseointegrative promoting silane containing a secondary amine 
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has been selected in order to investigate the effects of primary vs secondary amines 
in terms of antimicrobial efficacy. 
In this chapter, Ti has been functionalised with two different aminosilanes and 
subsequently tethered diazeniumdiolates on. A comprehensive mechanistic study of 
developed NO releasing coatings has been carried out to understand the kinetics and 
payload of release as a function of the stability of the silane, the nature of the amino 
functional group and pH of release. This mechanistic understanding will allow fine 
tuning of the antimicrobial efficacy to prevent infection at 6 h (time frame for initial 
bacterial adhesion vs. mammalian cell adhesion) in the so called “race to the 
surface”. The antimicrobial efficacy against Staphylococcus aureus and Pseudomonas 
aeruginosa have been studied at 6 and 24 h and cytocompatibility of the surfaces 
with primary human osteoblast cells was investigated in order to improve the 
integration of implants with bone.  
3.2 Materials and Methods  
3.2.1 Experimental Materials  
Ti rods (ø 6.4mm, 99.7% metal basis) were purchased from Alfa Aesar and cut into 
pieces 1.5 mm in thickness. 6-Aminohexyl-3-aminopropyl trimethoxysilane (AHAP3, 
95%), 11-Aminoundecyltriethoxysilane (AUTES, > 95%), n-Decyltrimethoxysilane 
(DTMS, 97%) were purchased from Fluoro Chem. Ethanol, acetic acid (HAc), sodium 
acetate (NaAc), Luria Bertani Broth (LB Broth), LB agar, Dulbecco’s Modified Eagle 
Medium (DMEM), fetal bovine serum (FBS), Penicillin-Streptomycin, Trypsin-EDTA 
solution, formaldehyde solution and Triton™ X-100 were purchased from Sigma-
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Aldrich. 4′,6-diamidino-2-phenylindole (DAPI) staining mounting gel and ActinGreen 
™ 488 reagent kit were obtained from Thermo Fisher Scientific.  
3.2.2 Titanium Pretreatment  
Ti discs were polished with SiC sand paper (1200-grit) and then washed with ethanol 
and DI water for 15 mins each. Washed Ti discs were then air dried at room 
temperature and stored in a desiccator until use. 
3.2.3 Silanisation and Diazeniumdiolate-Functionalisation 
Pristine polished Ti discs were immersed in 10 wt % silane solutions (Amino-silanes: 
AHAP3, AUTES and Control alkyl silane: DTMS) prepared in ethanol and shaken on a 
gyro-rocker (SSL3, Stuart) at 70 rpm for 4 h. Samples were then washed with ethanol 
3 times to remove unreacted silane and cured in an oven at 80° C for 4 h. At the end 
of this time, samples were then stored in a desiccator until diazeniumdiolate 
functionalisation. Silanised samples are referred to as AHAP3, AUTES and DTMS, 
respectively. Silanised Ti discs were functionalised with diazeniumdiolates in an in-
house built stainless steel NO reactor as previously reported.141 Briefly, the reactor 
chamber was purged with 6 bar argon (BOC, Guildford, UK) for 5 mins (3 x) and 10 
mins (3 x) to remove atmospheric oxygen and water. Then nitric oxide (NO) (BOC, 
Guildford, UK) was introduced into the reactor at 5 bar for 3 days. At the end of this 
time, residual NO was removed by flushing the chamber with 6 bar argon for 5 mins 
(2 x) and 10 mins (2 x). Diazeniumdiolate functionalised Ti samples were then stored 
at -20°C until use. Diazeniumdiolate functionalised samples are referred to as Ti/NO, 
AHAP3/NO, AUTES/NO and DTMS/NO, respectively. It should be noted that titanium 
samples will have an oxide layer on the surface and most likely exist as TiOx. 
51 
 
Moreover as Ti and DTMS do not possess any amine functionality, there is no 
possibility of forming N-diazeniumdiolates, and as such these are control samples. 
The nomenclature is kept as Ti/NO and DTMS/NO for consistency and ease of 
readership.  
3.2.4 Characterisation 
3.2.4.1 Contact Angle Analysis 
Static contact angles (Attension ThetaLite, Biolin Scientific, Västra Frölunda, Sweden) 
were used to determine the changes in surface wettability of all samples. The sessile 
drop method was used and contact angle measurement images were taken using 
OneAttension software (Biolin Scientific, Västra Frölunda, Sweden). Three random 
spots were performed per sample type (n=3) and mean values ± standard deviations 
of the samples were recorded and repeated twice.  
3.2.4.2 Atomic Force Microscopy Analysis  
Atomic force microscopy (AFM) was used to observe the surface topography changes 
of silanised samples (Bruker Multimode 8 fitted with a NanoScope V controller; 
Bruker, Billerica, MA, USA). Samples were imaged in air in ScanAsyst mode using a 
silicon RTESPA-525 tip, operating at a scan rate of 0.9 Hz. At least three replicate 
regions including the centre and edge of 10 x 10 µm2 of each sample were imaged 
and repeated twice. The mean roughness (Ra) and root mean square roughness (Rq) 
were measured using Bruker NanoScope Analysis 1.7 software. 
3.2.4.3 X-ray Photoelectron Spectroscopy 
Functionalised surfaces were analysed by X-ray photoelectron spectroscopy (XPS) on 
an Axis-Supra instrument from Kratos Analytical with monochromatic Al Kα radiation 
(225W). Survey scan spectra were recorded at a pass energy of 160 eV and a 1 eV 
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step size. High resolution scans were acquired at a pass energy of 20 eV and a 0.1 eV 
step size. The XPS spectra were recorded in normal emission. Three random areas on 
each sample were analysed and the results are reported as the mean average atomic 
percentage concentration (at. %) ± standard deviations. Spectra were processed 
using CasaXPS 2.3.19PR1.0 software (Casa software, UK) and charge calibrated to C 
1s at 284.8 eV. Spectra were curve fitted with a mixed Gaussian-Lorentzian function 
after Shirley background subtraction.  
3.2.4.4 NO Release Measurement 
Nitric oxide release from samples was measured using a Sievers 280i 
Chemiluminescence Nitric Oxide Analyser (NOA280i, GE, USA). The instrument 
measures nitric oxide based on a gas-phase chemiluminescent reaction between 
nitric oxide and ozone: 
NO + O3 → NO2* + O2  
NO2* → NO2 + hv  
Emission from electronically excited nitrogen dioxide is in the red and near-infrared 
region of the spectrum, and is detected by a thermoelectrically cooled, red-sensitive 
photomultiplier tube. Before measurement, calibration was carried out by using zero 
air filter and 89.2 ppm NO (g) (balance nitrogen). The diazeniumdiolate 
functionalised samples (6.4 mm diameter, 1.5 mm thick) were immersed in 5 ml of 
acetic acid buffer (pH 4) or phosphate buffered saline (PBS; pH 7.4 and pH 8.5) at 
room temperature in a three-neck round bottom flask. Nitrogen gas was 
continuously sparged though the buffer at a flow rate of 200 ml / min. A vacuum 
pump connected with the NOA is used to draw the mixed gases in to the reaction cell 
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and maintains the pressure of the reaction cell. Nitric oxide release was measured at 
an interval of 1 s over more than 20 h. Each sample was measured in triplicate. 
3.2.5 Biofilm Assay and Morphology Analysis 
3.2.5.1 LB Broth and Agar Plates Preparation  
Fresh LB broth and LB agar plates were prepared prior to use. LB broth and LB agar 
powders were dissolved in deionised water with a concentration of 20g/L and 35g/L, 
respectively, followed by 15 minutes autoclave sterilisation at 121 °C. The sterilised 
LB broth was used after cooling down to room temperature. The sterilised LB agar 
plates were poured in aseptic condition and left to solidify at room temperature. All 
the broth and agar plates were stored at 4°C for further use.    
3.2.5.2 General Bacterial Culture 
Staphylococcus aureus (S. aureus) ATCC 25923 and Pseudomonas aeruginosa (P. 
aeruginosa) PA01 were used to evaluate the biofilm inhibition efficiency of the nitric 
oxide releasing surfaces. Overnight cultured bacteria were diluted to 106 CFU/mL 
according to McFarland Standards in LB broth. Samples were placed in a 48 well-plate 
and 500 µL diluted bacterial solution was added to each well before incubating at 37 
°C to allow biofilm formation.  
3.2.5.3 Biofilm Assay 
After incubation, samples were gently washed with PBS once to remove any 
unattached planktonic bacteria and then 1 mL of fresh LB broth was used to remove 
and re-suspend the biofilms. The bacterial CFU was determined after serial dilution 




3.2.5.4 Bacterial Morphology Analysis 
After incubation with bacteria, the samples were gently washed with PBS to remove 
unattached bacteria, and fixed with 2.5% glutaraldehyde solution in sterile PBS for 4 
h at 4 °C, then dehydrated with increasing concentrations of ethanol (30, 50, 75, 90, 
95, and 100 v/v %) for 10 min. After drying the samples were coated with gold (Q150T 
ES sputter coater; Quorum, East Sussex, UK) before SEM imaging (JSM 7001F 
FEGSEM; JEOL, Tokyo, Japan).  
3.2.6 In Vitro Cell Culture and Immunocytochemistry Analysis  
Primary human osteoblast cells used in this thesis were obtained from Institute of 
Aging and Chronic Disease (University of Liverpool, UK). The original passage cultured 
from explants of human bone from ethically approved osteoarthritis surgery.272 Cells 
were expanded and maintained in vitro in DMEM media supplemented with 10% FBS 
and 1% penicillin-streptomycin in a humidified atmosphere of 5% CO2 at 37 °C and 
used between passages 5 and 10. Upon confluence cells were rinsed in sterile PBS 
and incubated with trypsin-EDTA for 3 minutes at 37 °C to remove the cells from 
tissue culture polystyrene (TCPS) and retain in solution, diluted to 1 x 105 cells/ml 
using the afore mentioned culture medium. Samples were incubated with 1 ml of cell 
suspension per well in 24-well culture plates. The media was replaced with fresh cell 
culture media every 3 days.  
At day 7 of culture, cells were prepared for staining using the following protocols. 
Medium was removed from the wells and samples were rinsed with sterile PBS for 5 
minutes at 37 °C. Cells were then fixed using 4% formaldehyde for 15 min at room 
temperature, followed by rinsing with PBS. Then cells were permeabilised with 0.5% 
Triton® X-100 for a further 15 min at room temperature. After washing 3 times with 
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PBS, cells were incubated with diluted Oregon Green PhallodinTM 488 kit (5µg/ml) 
for 30 min at 4°C followed by further rinsing with PBS prior to mounting with DAPI 
staining mounting medium (Vector, UK). Cell morphology images were obtained by 
confocal laser scanning microscopy (LSM 510, Zeiss, Germany). 6 images were taken 
per samples and representative images are shown. Images were processed using 
ImageJ 1.48 software.  
3.2.7 Statistical Analysis  
One-way analysis of variance (ANOVA) was used to analyse the differences among 
various treatment samples. The Student-Newman-Keuls (SNK) method was carried 
out to determine significance between treatment types. A value of p < 0.05 was taken 
as being statistically significant.  
3.3 Results and Discussion 
3.3.1 Synthesis of N-Diazeniumdiolate-Functionalised Titanium  
The diazeniumdiolate functionalised Ti surfaces were synthesised via a two-step 
method illustrated in Figure 3.1. Polished Ti surfaces were functionalised with silanes 
with or without primary and secondary amines; 6-Aminohexyl-3-aminopropyl 
trimethoxysilane (AHAP3): 1 primary amine and 1 secondary amine, 11-
Aminoundecyltriethoxysilane (AUTES): 1 primary amine and n-Decyltrimethoxysilane 
(DTMS): no amine. The silane-modified Ti substrates were then exposed to high 





Figure 3.1: Diazeniumdiolate functionalisation of titanium surfaces. 
3.3.2 Surface Wettability: Static Water Contact Angle  
The wettability of the Ti substrates before and after functionalisation was 
determined using static contact angles with the results shown in Figure 3.2. Pristine 
Ti had an average contact angle of 64°. After silanisation, the contact angles for 
AHAP3, AUTES and DTMS films on Ti increased to 78, 83 and 101°, respectively. The 
increase in contact angle can be attributed to the presence of hydrophobic alkyl 
silane chains confirming functionalisation of the surface. DTMS displayed the most 
hydrophobic character, as there is no electronegative amino group present in the 




Figure 3.2: Measurement of contact angle with water drops at room temperature on 
pristine Ti (p_Ti) and silanised p_Ti with AHAP3, AUTES and DTMS. Each bar 
represents mean ± SD (n=3). *p < 0.05, relative to the control.  
3.3.3 Surface Topography: Atomic Force Microscopy  
The topography of Ti and functionalised Ti surfaces was investigated using AFM 
(Table 3.1 and Figure 3.3). Pristine Ti has a roughness of 35.5 ± 0.8 nm (Ra) (Figure 
3.3a) and all of the silanised surfaces showed a statistically significant increase in 
roughness (Figure 3.3b- d). This is indicative of the deposition of multiple layers of 
silane on the surface. Indeed there is visible aggregation of the silane observed on all 
of the silanised surfaces (Figure 3.3b-d). The silanised surfaces displayed roughness 
values (Ra) of: AHAP3 (108.1 ± 16.4 nm), AUTES (87.1 ± 8.7 nm) and DTMS (64.8 ± 




Table 3.1: Topography of silanised surfaces. 
roughness p_Ti AHAP3 AUTES DTMS 
Rq (nm) 46.4 ± 2.1  135.0 ± 26.0 a 109.2 ± 9.1 a 80.9 ± 22.0  
Ra (nm) 35.5 ± 0.8  108.1 ± 16.4 a 87.1 ± 8.7 a 64.8 ± 17.4 a 






Figure 3.3: AFM height mode of silanised surfaces. The cross-sections of 10 × 10 µm2 
size images are shown at different z-axis maximum heights. a) p_Ti, b) AHAP3, c) 




3.3.4 Surface Chemistry: X-ray Photoelectron Spectroscopy  
The surface chemistry of the silanised surfaces pre- and post- diazeniumdiolate 
treatment were analysed by XPS with the resultant at. % shown in Table 3.2. XPS 
analysis shows that pristine Ti consists of Ti, C, O and N. After silanisation with all 3 
silanes, the Ti 2p peak decreases with an increase in the C 1s peak and introduction 
of the Si 2p peak, confirming the silanisation of the surface. Following exposure of 
the silanised Ti surfaces to NO, the at. % of the C 1s peak decreases with a 
concomitant rise in the O 1s and N 1s peaks confirming formation of the N-
diazeniumdiolate functional group.  
 
Table 3.2: Atomic surface concentration (at. %) of pristine ti surface, silanised 
surfaces and diazeniumdiolates-functionalised surfaces. 
sample  C (1s) O (1s) N (1s) Ti (2p) Si (2p) 
p_Ti 28.2±1.4 52.2±0.8 0.6±0.5 18.9±1.1 - 
AHAP3 63.9±5.3 15.2±5.4 9.6±1.4 1.3±2.3 9.9±1.2 
AUTES 75.0±0.3 11.5±0.2 3.7±0.4 - 9.8±0.2 
DTMS 47.9±0.8 34.4±0.5 1.7±0.3 11.7±0.5 4.2±0.3 
Ti/NO 49.3±2.7 39.4±2.2 1.7±0.8 9.5±1.3  - 
AHAP3/NO 57.1±1.2 26.4±1.1 10.3±0.3 0.6±0.5 5.5±0.2 
AUTES/NO 71.5±0.2 17.8±0.2 1.8±0.5 0.1±0.1 8.8±0.4 





Table 3.3: XPS derived N 1s curve fitted data for the surfaces. 
sample 
N 1s 
N-H N+ N-O 
by-products 
(NO2-, NO3-, NO4-) 
p_Ti 69.1 30.9 - - 
AHAP3 83.1 16.9 - - 
AUTES 75.8 24.2 - - 
DTMS 75.1 24.9 - - 
Ti/NO 55.7 - - 44.3 
AHAP3/NO 12.1 22.9 25.4 39.6 
AUTES/NO 14.7 28.8 31.5 25.0 
DTMS/NO - 72.0 28.0 - 
 
The silanisation and functionalisation with diazeniumdiolate can also be 
corroborated by analysing the curve fitted high resolution N 1s spectra shown in 
Figure 3.4 (with the associated quantitative information given in Table 3.3). The 
presence of nitrogen on pristine Ti (Figure 3.4a) is due to the nitrogen contamination 
of the raw material (N: 0.02% in Ti rod, data from certificate of analysis document, 
Alfa Aesar). Following silanisation with the aminosilanes, AHAP3 and AUTES, two 
additional states of nitrogen observed, with binding energies at ~400.5 eV (N-H) and 
~401.6 eV (N+) (Figure 3.4c and e). After exposure to high pressures of NO, 
diazeniumdiolate formation was confirmed via the presence of the new peaks 
observed, indicative of N-H (400.5 eV), N-O (402.3 eV), and NO4- (~407 eV) bonds. 
Moreover, the presence of the N-O bond is observed with a decrease in the N-H 
bond, confirming the nucleophilic attack of the amine group on the NO dimer forming 
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the diazeniumdiolate functional group. Interestingly, DTMS does not have any 
pendant amino groups but after exposure to NO gas, the N 1s envelope shows the 
presence of N-O peak (28%). This is probably due to some physisorbed NO on the 







Figure 3.4: High-resolution N 1s spectra of (a) p_Ti, (b) Ti/NO, (c) AHAP3, (d) 
AHAP3/NO, (e) AUTES, (f) AUTES/NO, (g) DTMS and (h) DTMS/NO. The peak at ~401.6 
eV represent –N+ and the N-O bond shows a bonding energy at ~402.3 eV, shows 
successful formation of diazeniumdiolates. 
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3.3.5 NO Release from Diazeniumdiolate-Functionalised Surfaces  
In order to understand the effects of pH on NO release, the NO-payload from the 
diazeniumdiolate-modified surfaces was determined using a chemiluminescence 
nitric oxide analyser in acetate and PBS buffers at pH 4, 7.4 and 8.5. The NO release 
profiles of Ti/NO, AHAP3/NO, AUTES/NO and DTMS/NO are shown in Figure 3.5 (a-
e). The total concentration of NO after 1 hr (t[NO]), half-life of NO release (t1/2), 
maximum instantaneous NO release concentration ([NO]m), time required to reach 
[NO]m (tm) and NO release duration (td) from each surface were determined and the 
values are summarised in Table 3.4. The NO payload and release kinetics were 
dependent upon the number and class of amines in the silane, the pH of the release 








Figure 3.5: Chemiluminescence NO release profiles of (a) overall 20 h and the insert 
is rescaling of the first 0.4 hr at pH 4, (b) rescale detailing over 20 h at pH 4, (c) overall 
20 h and the insert is rescaling of the first 0.2 hr at pH 7.4, (d) rescale detailing over 
20 h at pH 7.4 and (e) overall 20 h at pH = 8.5 buffers at room temperature. The 
inserts have the same scaling units of the axis as the overall pictures. (f) primary and 
secondary amine based diazeniumdiolates decomposition as NO/HNO donor at 




AHAP3/NO: At pH 4, AHAP3/NO surfaces released NO at a maximum instantaneous 
NO release concentration of 1.8 µM·s-1 with 1005.4 µM NO being released in a burst 
during the first hour. At pH 7.4, the concentration of NO released was less than that 
observed at pH 4, with 676.8 µM of NO released during the first hour. At pH 8.5, the 
AHAP3/NO surface released a NO concentration of 330.5 µM during the first hour. 
AUTES/NO: At pH 4, AUTES/NO surfaces released a maximum instantaneous NO 
release concentration of 5.6 µM·s-1 and 1883.6 µM NO was released in a burst during 
the first hour. At pH 7.4, the concentration of NO released was less than that 
observed at pH 4. 476.2 µM of NO was released during the first hour. At pH 8.5, the 
AUTES/NO surface released 133.7 µM during the first hour.  
DTMS/NO: At pH 4, DTMS/NO surface, released 231.1 µM of NO with a maximum 
instantaneous NO release concentration of 0.4 µM·s-1. At pH 7.4, the concentration 
of NO released was less than that observed at pH 4. The final concentration of NO 
released was 26 µM during the first hour. At pH 8.5, the DTMS/NO surface released 
no measurable NO. DTMS/NO has no amine in its backbone and therefore cannot 








Number of amine t[NO]  t[NO]  t1/2 [NO]m tm td 
 primary secondary (µM) (µM·cm-2) (min) (µM·s-1·cm-2) (min) (h) 
 AHAP3 1 1 1005.4 3122.4 34.2 5.6 7.4 18.1 
pH 4 AUTES 1 0 1883.6 5849.7 52.8 17.4 3.2 3.2 
 DTMS 0 0 231.1 717.7 8.0 1.3 4.5 0.8 
 AHAP3 1 1 676.8 2101.9 16.3 3.1 2.7 16.5 
pH 7.4 AUTES 1 0 476.2 1478.9 2.4 10.2 1.5 1.5 
 DTMS 0 0 26.0 80.7 0.2 0.3 2.1 0.7 
 AHAP3 1 1 330.5 1026.4 183.9 0.9 5.6 20+ 
pH 8.5 AUTES 1 0 133.7 415.2 159.8 0.3 5.3 10 






3.3.6 Mechanism of NO Release  
The mechanism of NO release is dependent on three factors as described below: pKa 
of the amine, class of amine (primary vs secondary) and quality of the silane layer 
formed on the surface. 
pKa: The NO release from diazeniumdiolate occurs via protonation of the amine 
precursor and the release kinetics are dependent upon the pKa of the amine. As such, 
the higher the pKa the easier the protonation and the faster the release at 
physiological conditions. The rate of release of NO can also be increased by other 
factors such as the presence of neighboring amines which can act as a proton 
source139 and an increase in temperature.273 This is indeed what was experimentally 
observed for the AHAP3/NO and the AUTES/NO surfaces; at pH 4 these surfaces 
showed a burst release of NO.  
Class of amine: Keefer and coworkers have demonstrated that primary 
amine diazeniumdiolates decompose to HNO and NO with the product ratio 
dependent on the pH and the basicity of the nitroso oxygen formed.268 In contrast, 
secondary amines only undergo decomposition based on pH mediated protonation 
to produce exclusively NO.268 A schematic has been shown in Figure 3.5 (f). Keefer 
has shown that primary amine diazeniumdiolates decompose: (a) exclusively to NO 
at pH 5; (b) to a mixture of HNO and NO at pH 5-8, and (c) exclusively to HNO above 
pH 8. In this chapter, AHAP3/NO has the potential to form one secondary and one 
primary amine diazeniumdiolate and AUTES/NO has the potential to form only a 
primary amine diazeniumdiolate. Therefore, based on Keefer’s mechanism,268 
AHAP3/NO and AUTES/NO will release the highest concentration of NO at pH 4 as 
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both the primary and secondary amines exclusively decompose to NO. The 
concentration of NO will then decrease as the pH of the release buffer increases due 
to the presence of primary amines and subsequent decomposition to HNO. Despite 
the AHAP3 releasing lower amounts of NO at pH 4 (1005.4 µM) than the AUTES (1883 
µM), the release concentration exceeds the concentration released by AUTES at pH 
7.4 due to the presence of a secondary amine in AHAP3.  
Number of amines/Quality of silane layer: AHAP3 has one secondary amine and one 
primary amine and therefore the potential to form of two diazeniumdiolates and 
have double the payload of NO at pH 4. In solution, this is indeed what is observed, 
where AHAP3/NO (10 µl/5 ml PBS) shows a maximum NO release of 1993.3 µM·s-1, 
in comparison with AUTES (Figure 3.6). However, the opposite was observed when 
the silanes were immobilised on the surface, with AHAP3/NO and AUTES/NO having 
NO payloads of 1005.4 µM and 1883.6 µM within the first hour. The lower payload 
observed here is due to the quality of the silane monolayer formed.  
A more cohesive silane coverage on Ti surfaces should yield a higher NO payload. 
AUTES forms a monolayer on the surface through hydrolysis of an ethoxy leaving 
group to generate silanol containing species that readily condenses on the surface. 
The faster the hydrolysis of the silane, the faster the condensation and the increase 
in the self-condensation/aggregation reactions (a less cohesive monolayer is formed 
on the surface). The rate of hydrolysis of the alkoxy groups are dependent on their 
size (CH3O>C2H5O>t-C4H9O), meaning that a methoxysilane hydrolyses 6 - 10x quicker 
than an ethoxysilane.202-203, 274-275 Therefore, as ethoxysilanes hydrolyse slower than 
methoxysilanes, they will form more cohesive monolayers on the surface. In this 
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chapter, AHAP3 is a methoxysilane and AUTES is an ethoxysilane. This explains why 
AHAP3/NO on the surface has a lower NO payload when on the surface compared 
with AUTES/NO, despite the situation being reversed in solution phase (Figure 3.6). 
 
 
Figure 3.6: NO release of liquid AHAP3/NO and AUTES/NO measured in pH4 PBS. 
 
3.3.7 Antimicrobial Analysis  
Gram-positive S. aureus, and gram-negative P. aeruginosa, two relevant pathogens 
for orthopaedic infections,53 were selected to measure the antimicrobial efficacy of 
NO releasing samples. The SEM micrographs of S. aureus and P. aeruginosa cultured 
for 6 h on Ti, AHAP3, AUTES and DTMS samples with/without NO release are shown 
in Figure 3.7. Bacterial clusters and biofilms can clearly be observed on pristine Ti (as 
shown in Figure 3.7a (i)), and all non-NO releasing silanised surfaces (AHAP3, AUTES, 
and DTMS, Figures 3.7b-d (i) respectively) demonstrating that these surfaces do not 
exhibit antimicrobial activity. Tethering of the diazeniumdiolate to the 
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aminosilanised surfaces AHAP3/NO (Figure 3.7b (ii, iv)) and AUTES/NO (Figure 3.7c 
(ii, iv)) demonstrate a reduction in the S. aureus and P. aeruginosa adhered to the 
surface, in comparison to Ti/NO (Figure 3.7a (ii, iv) and DTMS/NO (Figure 3.7d (ii,iv)). 
This is in agreement with the results presented in Figure 3.5, which demonstrates 
that the surfaces that release the highest payload of NO exhibit the most 
antimicrobial activity.  
The prevention of biofilm formation on all surfaces at 6 and 24 h was determined by 
using a biofilm CFU assay and the results are presented in Figure 3.7e for S. aureus. 
The AHAP3/NO surface showed a reduction in the number of adhered S. aureus from 
0.8×108 CFU/ml to ~106 CFU/ml at 6 h which corresponds to a 1.5 log reduction 
(Figure 3.7e). Likewise, the AUTES/NO surface showed a reduction in the number of 
adhered S. aureus from 4.1×107 CFU/ml to ~106 CFU/ml at 6 h which corresponds to 
a 0.8 log reduction (Figure 3.7e). At 24 h, the reduction in the adhered bacteria is 
approx. 1.5 log for AHAP3 to AHAP3/NO and 0.8 log for AUTES to AUTES/NO. This 
difference in antimicrobial activity is in agreement with the results presented in Table 
3.4 which show that the AHAP3/NO surface has a higher payload of NO at pH 7.4 
(676.8 µM) vs AUTES/NO (476.2 µM). The surface of Ti/NO and DTMS/NO did not 
show any reduction in the adhered bacteria. A salient point here is that the NO 
release profiles were carried out in 5 mL of measurement buffer, whilst, the 
antimicrobial experiments were carried out in 500 μL of broth. Hence the bacteria in 
these experiments are exposed to 10x the payload observed in the NO release 
profiles and within the reported range need for antimicrobial activity by Friedman 
and coworkers.106  
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The prevention of biofilm formation on all surfaces at 6 and 24 h was determined by 
using a biofilm CFU assay and the results are presented in Figure 3.7f for P. 
aeruginosa. The AHAP3/NO surface showed a reduction in the number of adhered P. 
aeruginosa from ~105 CFU / ml to 1.6×104 CFU / ml at 6 h which corresponds to a 0.8 
log reduction (Figure 3.7f). Likewise, the AUTES/NO surface showed a reduction in 
the number of adhered P. aeruginosa from 1.6×105 CFU / ml to 3×104 CFU / ml at 6 
h which corresponds to a 0.8 log reduction (Figure 3.7f). At 24 h, the reduction in the 
adhered bacteria is approx. 0.3 log for AHAP3 to AHAP3/NO and there was no 
significant reduction for AUTES to AUTES/NO. This difference in antimicrobial activity 
is in agreement with the results presented in Table 3.4 which show that the 
AHAP3/NO surface has a higher payload of NO at pH 7.4 (676.8 µM) vs AUTES/NO 
(476.2 µM). The surface of Ti/NO and DTMS/NO did not show any reduction in the 
adhered bacteria. As mentioned above, as the antimicrobial experiments are carried 
out in only 500 µl of broth, the bacteria are exposed to 10x the payload observed in 
the NO release profiles and within the reported range need for antimicrobial activity 






Figure 3.7: SEM images of (a(i) to d(ii)) S. aureus and (a(iii) to d(iv)) P. aeruginosa after 
6 h growth on a(i and iii) Ti and (ii and iv)Ti/NO, b(i and iii) AHAP3 and (ii and 
iv)AHAP3/NO, c(i and iii) AUTES and (ii and iv)AUTES/NO, d(i and iii) DTMS and (ii and 
iv)DTMS/NO. Inserts in a-d are enlargements of the figures. The scale bar represents 
10 µm and 1 µm in insets. (e) S. aureus and (f) P. aeruginosa colonies formation on 
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the surfaces after 6 h and 24 h incubation. * p < 0.05 and ** p < 0.01 from control, 
and # p < 0.05 and ## p < 0.01 from corresponding silane. 
3.3.8 Cell Morphology  
The morphology of human primary osteoblasts was studied on the various surfaces 
at 7 days post seeding using confocal laser scanning microscopy (Figure 3.8). As 
expected, the osteoblasts present on the control surfaces (pristine Ti (Figure 3.8a(i)) 
and DTMS (Figure 3.8d(i)) were well spread with a high contact area, a complex 
network of actin fibres and displayed characteristic cobblestone morphology 
associated with adherent functional osteoblasts. NO treatment of the control 
surfaces (pristine Ti (Figure 3.8a(ii)) and DTMS (Figure 3.8d(ii)) did not affect the 
morphology of the cells. On the AHAP3 (Figure 3.8b(i)) and the AUTES (Figure 3.8c(i)), 
the osteoblasts had a shrunken morphology, poor actin cytoskeletal formation and 
there were fewer cells. In direct comparison, qualitative analysis of the cell response 
to the AHAP3/NO and AUTES/NO surfaces revealed a more positive expression in 
terms of cell response. Qualitative analysis of these surfaces demonstrated that 
when cells were cultured in contact with AHAP3/NO (Figure 3.8 b(ii)) cells were well 
adhered and spread with a distinctive formation of stress fibres through the body of 
the cells. Cells cultured in contact with AUTES/NO (Figure 3.8c(ii)) demonstrated an 
elevated level of cell adhesion and actin formation compared to AHAP3 surfaces, and 
even showed formation of the characteristic cobblestone morphology that is 






Figure 3.8 Fluorescence images of human osteoblasts spreading on a(i) Ti and 
(ii)Ti/NO, b(i) AHAP3 and (ii) AHAP3/NO, c(i) AUTES and (ii) AUTES/NO, d(i) DTMS and 
(ii) DTMS/NO after 7 days incubation. Representative images, n = 6 per group. Scale 




3.4 Conclusion  
The prevention of bacterial adhesion and biofilm formation whilst promoting 
osteointegration remains a significant medical challenge. An efficient NO-releasing 
coating on Ti surfaces has been developed. A key focus of this study was to 
understand mechanistically how aminosilanes tether to the surface and how the 
nature of the aminosilane precursor affects the resultant NO releasing properties in 
terms of payload and release kinetics, whilst acting as an initiator for adherence and 
function of osteoblast cells. The ability of the variously modified surfaces to prevent 
biofilm formation was evaluated, with both the AHAP3/NO and AUTES/NO surfaces 
displaying similar antimicrobial efficacy despite having differing inherent NO loading 
capabilities. Of particular interest is that both AHAP3/NO and AUTES/NO surfaces 
were capable of prevention of biofilm formation while not displaying cytotoxicity 




Chapter 4 Antimicrobial Nitric Oxide Releasing Porous Titanium 
Foams  
4.1 Introduction 
Aseptic loosening and biomaterials related infection are the two leading causes of 
orthopaedic implant failure. Over 10% of implants require the second operation 
within 15 years of the initial surgery because of aseptic prosthesis loosening.276 There 
are several unmet clinical needs pain this area that include complex bone 
reconstruction, large bony defects and patients with compromised bone metabolism 
and immune systems (for example people with bone cancers) that drive research in 
this area.277 Ti and its alloys are widely for these applications, due to its good 
biocompatibility, mechanical property and corrosion resistance. Ti foams recently 
attracted more attentions, compared with Ti material itself, because of its advantage 
porous structures, giving better bonding strength at the implant-bone interfaces and 
match elastic modulus for improved osseointegration.278-279 Porous titanium 
implants (foams) are promising materials for hard tissue regenerative applications as 
they have been proved to improve the bond between tissue and implants due to the 
interconnected pores which can facilitate the ingrowth of bone tissue.280 Another 
advantage of using titanium foams in orthopaedic implant application is that the 
mechanical properties can be tailored to match the requirement of the bone defect 
as the mechanical properties are due to the pore size distribution and volume 
fraction.281 Indeed, Yavari et al.282 have recently shown that large surface area 
associated with porous titanium implants has led to an upregulation of osteogenic 
markers in vitro and has shown increased biomechanical properties in vivo.   
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Most manufacturing process used to fabricate porous metallic foams to date use 
additive manufacturing which requires expensive equipment. Within this chapter a 
novel titanium foams fabricated using a novel in house manufacturing technique and 
its feasibility for use for orthopaedic implants has been investigated. The Lost 
Carbonate Sintering (LCS) process is a representative space holder manufacturing 
process developed at Liverpool by Zhao et al.,211 and is a cost-effective method used 
to manufacture metallic foams with highly controllable porosity, pore size and pore 
shape. This technique has been used for many applications in energy, aerospace and 
civil engineering,212-215 but never studied in the biomedical arena. The porous metals 
produced by this route demonstrated mechanical properties in terms of elastic 
modulus and compressive strength.211, 283 
In addition to the investigating the feasibility of using LCS manufactured titanium 
implants to provide materials that will demonstrate increased osteogenic function, 
these materials will also be modified with a surface coating to prevent implant 
associated infection, which is the other major cause of failure. Once bacteria adhere 
to an implanted biomaterial, they form biofilms which are notoriously difficult to 
remove and often the only solution is removal of the implant. Oral delivery of 
antibiotics to clear the infection is ineffective once a biofilm has formed and can be 
problematic given the rise in multidrug resistant bacterial.   
NO, a free radical gas molecule, has been studied possessing functions in several 
physiological processes, including vascular relaxation, neurotransmission, immune 
response, wound healing, and bone remodelling.111, 125, 284-286 NO is also part of the 
body’s endogenous immune response to pathogens and has been heavily researched 
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as a broad-spectrum antimicrobial agent.36, 94, 141, 156, 287 However, owing to the short 
half-life of NO, a suitable chemical donor that can control the payload and rate of 
delivery could make this a promising alternative to the use of antibiotics.288 In the 
previous chapter, the functionalisation of flat titanium with two different 
aminosilanes with the subsequent tethering of diazeniumdioates onto the silanes has 
been studied. It has been demonstrated that the nature of the aminosilane 
precursors (AUTES and AHAP3) affects the resultant NO releasing properties in terms 
of payload and release kinetics, whilst acting as an initiator for adherence of 
osteoblast cells surfaces.269 In this chapter, AUTES/NO was selected to be coating on 
LCS-fabricated Ti foams to understand the effects of microarchitecture on the 
antimicrobial efficacy. The NO payloads on Ti foams with different AUTES 
concentration treatment were performed by chemiluminescence at pH4. The biofilm 
prevention and antimicrobial activity were characterised on E. coli and S. aureus for 
4 and 24 h culture.    
4.2 Materials and Methods 
4.2.1 Materials 
Commercially pure Ti powder with an average particle size of 45 µm was purchased 
from Ecka Granules Metal Powder Ltd. (Wednesdbury, UK). Food grade sodium 
chloride (NaCl) with a particle size range of 425 – 710 µm was purchased from E&E 
Ltd. (Melbourne, Australia). 11-Aminoundecyltriethoxysilane (AUTES, > 95%) was 
purchased from Fluoro Chem. All common laboratory solvents and salts, including 
ethanol, acetic acid (HAc), nitric aicd (HNO3), hydrochloric acid (HCl), disodium 
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phosphate and sodium acetate (NaAc), with analytic grade were from Merk KGGaA 
(Darmstadt, Germany) and used as received. 
Sample nomenclature is as follows: (a) the clean Ti foam termed as m_Ti; (b) silanised 
m_Ti termed using the concentration value of AUTES in silanisation, for example m_Ti 
silanised in 1% concentration of AUTES termed as 1%AUTES; (c) Diazeniumdiolate 
functionalised samples are termed as m_Ti/NO, 1%AUTES/NO, 5%AUTES/NO, 
10%AUTES/NO and 20%AUTES/NO. It should be clear here that there is no possible 
amine functionality on m_Ti which was used as a control group in the work, the 
nomenclature of m_Ti/NO is for consistency and readability.  
4.2.2 Manufacturing of Ti Foams 
Ti foams were obtained from Dr. Pengcheng Zhu who was using the Lost Carbonate 
Sintering process (LCS) as previously described by Zhao et al.211, 215 Briefly, Ti and NaCl 
powders were mixed at a volume ratio of 4:6 for manufacturing porous samples with 
porosity of 60%. The mixture was sealed in a cylindrical steel tube, then compacted 
at 200 MPa by a hydraulic press and sintered at 790 °C for 4 h. A large porous Ti was 
obtained after removing all the NaCl particles by dissolution route in water. Then the 
as-produced Ti foam was cut into disc shapes, with a diameter of 6 mm and a height 
of 2 mm, by using an electrical discharge machine Prima E250 (ONA Ltd., Bristol, UK). 
The Ti foams were washed in HNO3 and deionised water, then fully dried after 
autoclave sterilizing and stored in a desiccator before use. The LCS process is shown 




Figure 4.1: Schematic of the LCS process for manufacturing titanium foams. Image 
adapted from Zhao et al.211 with permission from Elsevier.  
      
4.2.3 Silanisation and Diazeniumdioate-Functionalisation  
Cleaned Ti foams immersed in different concentration of 1%, 5%, 10% and 20 % (v/v) 
AUTES/ethanol solutions and slowly vacuumed to no bubble appeared in solution, 
subsequently shaken on a gyro-rocker (SSL3, Stuart) at 70 rpm for 4 h. Samples were 
then washed with ethanol 3 x 5 min to remove unreacted silane and cured in an oven 
at 80°C for another 4 h. 
The treatment process of diazeniumdiolates functionalisation has been the same as 
described in Chapter 3 section 3.2.3.     
4.2.4 Scanning Electron Microscopy (SEM) 
The morphology of the Ti foam was examined by SEM. Sample m_Ti coated with gold 
by using Q150T ES sputter coater, images were subsequently captured on JSM 7001F 
field emission scanning electron microscope with a voltage of 10.0 kV. The energy 
dispersive X-ray spectroscopy (EDX) was used to characterise the elemental 




4.2.5 Brunauer-Emmett-Teller (BET) 
The surface area of Ti foams was measured by Dr Pengcheng Zhu using a 3Flex 3500 
gas sorption analyser at 77K.213 m_Ti and silanised foams were degassed at 300°C 
under vacuum for 3 h before measurement. Each sample measured in triplicates.         
4.2.6 Chemiluminescence 
Nitric oxide release from Ti foams was measured using a Sievers 280i 
Chemiluminescence Nitric Oxide Analyser (NOA280i, GE, USA). The 
diazeniumdiolates functionalised samples (6 mm diameter, 2 mm thickness) were 
immersed in 5 ml of acetic acid buffer (pH 4) at room temperature in a three-neck 
round bottom flask. Nitrogen gas was continuously sparged though the buffer at a 
flow rate of 200 mL/min. A vacuum pump connected with the NOA is used to draw 
the mixed gases in to the reaction cell and maintains the pressure of the reaction cell. 
Nitric oxide release was measured at an interval of 1 s over more than 20 h. Each 
sample was measured in triplicate. 
4.2.7 Antimicrobial Assays 
4.2.7.1 LB Broth and Agar Plates Preparation  
The LB broth and agar plates preparation have been the same as described in Chapter 
3 section 3.2.5.1.      
4.2.7.2 General Bacterial Culture 
Escherichia coli (E. coli) ATCC 10536 and Staphylococcus aureus (S. aureus) ATCC 
25923 were used to evaluate the antibacterial efficiency of the nitric oxide releasing 
foams. The operation has been the same as described in Chapter 3 section 3.2.5.2.  
4.2.7.3 Biofilms Colony Forming Unit (CFU) Assay on Adhered Bacteria 
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The overnight cultures of E. coli and S. aureus were diluted to 1 x 106 CFU/mL in LB 
broth, according to the absorbance @600 nm and a 0.5 McFarland Standard.289 Ti 
foams were placed in a 24 well-plate and 1 mL diluted bacterial solution was added 
to each well before incubating at 37 °C to allow bacteria growth and biofilm 
formation. After 4 h and 24 h incubation, foams were gently washed with PBS once 
to remove any unattached planktonic bacteria and then 1 mL of fresh LB broth was 
used to remove and re-suspend the biofilms. The bacterial CFU was determined after 
serial dilution of the bacterial suspension using the Miles and Misra method on LB 
agar plates.271   
4.2.7.4 Antimicrobial Activity Assay on Planktonic Bacteria 
The overnight cultures of E. coli and S. aureus were diluted to 1 x 106 CFU/mL in LB 
broth, according to the absorbance @600 nm and a 0.5 McFarland Standard.289 Ti 
foams were placed in a 24 well-plate and 1 mL diluted bacterial solution was added 
to each well before incubating at 37 °C to allow bacteria growth. After 4 h and 24 h 
incubation, the liquids in the well-plates were removed to another aseptic well-plate 
and serial diluted with LB broth. The antimicrobial activity on planktonic bacteria was 
determined using the Miles and Misra method on LB agar plates.271 
4.2.8 Immunofluorescence Live/Dead Assay   
Bacterial cell viability was performed using Live/Dead assay kit (L3224, 
ThermoFisher). After 4 h incubation with bacteria, Ti foams were transferred to a 
new aseptic well-plate and washed with aseptic PBS to remove unattached bacteria. 
Removed the washing liquid and added 300 µL of combined reagent solution 
(includes 4 µM Ethidium homodimer-1 (EthD-1) solution and 2 µM calcein AM) into 
each well. Subsequently incubated the cells in dark at room temperature for 30 mins. 
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The images then were captured by confocal laser scanning microscopy (LSM 510, 
Zeiss, Germany). 3 images were taken per sample and representative images are 
shown. Images were processed using ImageJ 1.48 software. 
4.2.9 Statistical Analysis  
One-way analysis of variance (ANOVA) was used to analyse the differences among 
various treatment samples. The Student-Newman-Keuls (SNK) method was carried 
out to determine significance between treatment types. All data were collected in 
triplicate and displayed as Mean ± Standard Deviation. A value of p < 0.05 was taken 
as being statistically significant.  
4.3 Results and Discussion 
4.3.1 Characterisation of Ti Foam 
4.3.1.1 Morphology and Elemental Analysis of Ti Foam 
The morphology and pore structure of the titanium foams was measures using SEM, 
with the corresponding elemental analysis studied using EDX spectroscopy. The pore 
structure of the Ti foam was examined by SEM (shown in Figure 4.2). It can be seen 
clearly that the pores were distributed homogeneously in sizes of approximately 500 
µm on the LCS m_Ti. Pores with sizes of 100-200 µm are also visible are found to 
interconnect large pores (shown in Figure 4.2a). This interconnectivity of pores can 
enable the potential tissue in-growth and vascularisation.290-291 Figure 4.2b presents 
a magnified pore open wall region of Figure 4.2a, which reveals a roughed surface, 
as a result of the presence of the solid TiO2 particles (in a size of ~10 µm). The 
microstructure of the prepared samples, containing pores with sizes from 100 to 500 
µm, present the characteristics of hierarchical metallic foams, which can be used to 
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mimic natural bones and provide necessary supports for attachment, proliferation 
and differentiation of bone cells.292-294  
 
Figure 4.2: a) SEM images of the LCS m_Ti, the scale bar represents 100 µm. b) 
presents the dash rectangle region in a), the scale bar represents 20 µm. 
 
The chemical analysis spectrum of m_Ti has been carried out by EDX as shown in 
Figure 4.3. Only Oxygen (O) and Titanium (Ti) elements have been detected, 
indicating the NaCl has been completely removed from the fabrication process. O 
displays weight percentage of 15.69% and atomic percentage of 35.78%. Ti displays 
weight percentage of 84.31% and atomic percentage of 64.22%. The atomic ratio of 






Figure 4.3: Elemental spectrum of m_Ti. The inserted table displays the element 
weight percentage and atomic percentage analysis on m_Ti.  
 
4.3.1.2 Surface Area  
The surface area of the Ti foams was evaluated using nitrogen adsorption isothermal 
analysis. The nitrogen adsorption isothermal plot of m_Ti, 5% AUTES and 20% AUTES 
measured at relative pressure (P/P0), was shown in Figure 4.4. The BET surface area 
results were calculated based on the isotherm plot. The BET surface area of m_Ti was 
measured at 1.5 m2 g-1. The silanised samples of 5%AUTES and 20%AUTES displayed 
larger BET surface areas of 6.1 and 5.2 m2 g-1, respectively, indicating the increased 





Figure 4.4: nitrogen adsorption isothermal plot of m_Ti (black, square), 5%AUTES 
(red, round) and 20%AUTES (blue, triangle).  
 
4.3.2 Chemiluminescence: Measurement and Mechanism of NO Release 
The NO payload from the diazeniumdiolates functionalised Ti foams was determined 
by using a chemiluminescence nitric oxide analyser in acetic acid buffer at pH 4. The 
NO releasing profiles of these Ti foams are shown in Figure 4.5. The kinetics of NO 
release, including the total concentration of NO (t[NO]), maximum instantaneous NO 
release concentration ([NO]m), time required to reach [NO]m (tm), and NO release 
duration (td), were determined from each modified foam, and the values are 
summarised in Table 4.2. It needs to be clarified here that the NO release profiles of 
the foams at pH 7.4 were not obtained due to the COVID19 lockdown. 
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Figure 4.5: Chemiluminescence NO release profiles of diazeniumdiolates 





Table 4.2: Kinetic analysis of NO release Ti foams at pH 4. 
pH Sample 
t[NO] [NO]m tm td 
(mM) (µM·s-1·cm-3) (min) (h) 
4 
1%AUTES/NO 1.2 4.0 13 6+ 
5%AUTES/NO 2.3 6.2 22 5+ 
10%AUTES/NO 0.9 1.1 28 10+ 
20%AUTES/NO 2.0 1.5 79 14+ 
m_Ti/NO 0.4 0.9 177 4+ 
 
 
NO release at pH 4 
1%AUTES/NO release NO at a maximum instantaneous NO concentration of 4.0 
µM·s-1·cm-3 at the 13 min with a total NO release concentration of 1.2 mM within 6 
h. 
5%AUTES/NO release NO at a maximum instantaneous NO concentration of 6.2 
µM·s-1·cm-3 at the 22 min with a total NO release concentration of 2.3 mM within 5 
h.  
10%AUTES/NO release NO at a maximum instantaneous NO concentration of 1.1 




20%AUTES/NO release NO at a maximum instantaneous NO concentration of 1.5 
µM·s-1·cm-3 at the 79 min with a total NO release concentration of 2.0 mM within 14 
h. 
m_Ti/NO release NO at a maximum instantaneous NO concentration of  0.9 
µM·s-1·cm-3 at the 177 min with a total NO release concentration of 0.4 mM within 
16 h. As a control group, there is no amino binding site on m_Ti, therefore the NO 
payload measured from m_Ti/NO results from the physiosorbed NO gas molecules 
on m_Ti foam.   
 
Mechanism of NO release from Ti foams 
It can be seen that the Ti foams treated with different concentration of AUTES display 
different NO release profiles. When the concentration of AUTES was lower than 10%, 
all the foams display a burst release of NO., indicating a smooth fluid flow occurs in 
between the pores which can effectively release the NO. The NO payload of 
5%AUTES/NO was of 2.3mM and is only about twice higher than that of 1%AUTES/NO 
with a value of 1.2mM, which theoretically supposed to be 5 times higher. This 
indicates that the silanisation efficiency on Ti foam is being hindered at these 
concentrations. The total NO payloads increased with increasing silane concentration 
up to 5% and then dropped when silanisation was higher than 10%. This indicates 
that, at these higher concentrations, multiple layers of the silane were forming which 
either prohibited more efficient NO loading onto the silane or resulted in blockage of 
the pore which prohibited effective release of NO. Interestingly however, for the 
20%AUTES/NO foam a stable NO release for over 6 h is observed (as shown in Figure 
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4.5). This implies that a thick silanised layer has been formed on regions where the 
pores unblocked, leading to over twice higher of the NO payload of 20%AUTES/NO 
foam than 10%AUTES/NO foam.  
Overall, the concentration of AUTES silane layer plays a key role in mediating the NO 
payloads and NO releasing life time. The effects of the different NO release amount 
and releasing period of these foams on microbiology tests will be further discussed 
in the following sections. 
4.3.3 Antimicrobial Analysis 
4.3.3.1 Biofilm Inhibition  
Approximately 80% of biomaterial-associated infection in orthopaedic surgeries are 
caused by bacterial biofilm.295 Therefore in this chapter, the antibiofilm response of 
the Ti foams has been evaluated against gram-negative E. coli and gram-positive S. 
aureus, which are relevant to orthopaedic implant infections.296-297 The 
measurement of NO release at pH 7.4 has not been done due to COVID-19 lockdown, 
this will have to be done in the future. According to the previous NO release data 
analysis in Chapter 3, the NO release of Ti foams at pH 7.4 is assumed to follow the 
same trend (t[NO]: 5% > 20% > 1% > 10%; [NO]m: 5% > 1% > 20% > 10%) at pH 4 
but with lower and longer releasing. The following analysis of the effects of different 
NO release samples on biofilm inhibition are based on this assumption.  
The prevention of biofilm formation on the Ti foams has been measured by a biofilm 
CFU assay. All samples were incubated with bacteria for 4 and 24 h to allow the 
biofilm formation. The planktonic bacteria were washed off and the biofilm bacteria 
were then removed and counted as shown in Figure 4.6. NO releasing Ti foams 
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displayed effective antimicrobial activity against E. coli during the 4 and 24 h 
incubation periods as shown in Figure 4.6(a). After 4 h incubation, compared with 
the control group m_Ti, sample m_Ti/NO presented ~0.5-log reduction on biofilm 
formation, 1%AUTES/NO presented ~1-log reduction, 5%AUTES/NO had the 
reduction at 1.6-log, while 10%AUTES/NO and 20%AUTES/NO showed ~0.6-log 
reduction. After 24 h incubation, control foams without NO have displayed significant 
number of colonies. All the AUTES/NO foams presented efficient biofilm prevention, 
which was shown as more than 2.4-log reduction (compared to m_Ti) and 0.9-log 
reduction (compared to m_Ti/NO), after 24 h incubation.   
NO release Ti foams also displayed effective antimicrobial activity against S. aureus 
during the 4 and 24 h incubation periods as shown in Figure 4.6(b). After 4 h 
incubation, compared with the control group m_Ti, sample m_Ti/NO presented ~2.4-
log reduction on biofilm formation, 1%AUTES/NO presented ~1.5-log reduction, 
5%AUTES/NO had 1.7-log reduction, 10%AUTES/NO displayed the largest reduction 
at ~1.9-log, and 20%AUTES/NO showed ~1.4-log reduction of biofilm formation. After 
24 h incubation, control Ti foams without NO releasing have displayed significant 
number of colonies. All the AUTES/NO foams presented efficient biofilm prevention, 
with more than 2.2-log reduction (compared to m_Ti), after 24 h incubation. It should 
be noted that due to the lockdown, S. aureus biofilm CFU assay has been done for 
only one run. Hence not enough data for its analysis here. But it is predicted to have 
more biofilm prevention than E. coli, because the adhesion of S. aureus has displayed 







Figure 4.6: a) E. coli and b) S. aureus colonies formation on the NO release Ti foams 
after 4 and 24 h incubation. *p < 0.05 from control; #p <0.05 from the corresponding 
silane concentration with no diazeniumdiolates functionalisation. (NOTE: two runs 
on E. coli and one run on S. aureus have been done here) 
 
The measurement of NO release at pH 7.4 has not been done due to COVID-19 
lockdown, this will have to be done in the future. According to the previous NO 
release data analysis in Chapter 3, the NO release of Ti foams at pH 7.4 is assumed to 
follow the same trend (t[NO]: 5% > 20% > 1% > 10%; [NO]m: 5% > 1% > 20% > 10%) 
at pH 4 but with lower and longer releasing. Based on this assumption, the 
prevention of biofilm formation on AUTES/NO foams is in agreement with the NO 
releasing profile. 1%AUTES/NO and 5%AUTES/NO displayed notably high burst NO 
release within the first half hour, implying the burst NO release efficiently kill E. coli 
at an early stage. Although 10%AUTES/NO displayed a long release last, the low 
[NO]m during the burst might not sufficient in killing E. coli.   
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It is of significantly interest that all AUTES/NO foams showed more than 2.4-log 
reduction of E. coli and S. aureus biofilm bacteria (after 24 h incubation. When 
comparing these results to the flat Ti samples in Chapter 3, the increased surface area 
from the Ti foam micro structure allows for a higher payload of NO, allowing for 
increased antimicrobial efficacy. This coupled with the increased potential for the 
porous scaffold to integrate, make these materials ideal for antimicrobial 
orthopaedic applications. 
4.3.3.2 Antimicrobial Activity on Planktonic Bacteria 
Planktonic bacteria play a key role in prevention of biofilm formation because it can 
freely attach onto the rest regimes of the implants in liquid environment. Bacteria 
cells are able to highly regulated alternate between the biofilm and the planktonic 
phase in their life cycles.300 Therefore, the antimicrobial capacity of the NO release 
foams has been investigated and analysed using colonies formation assays, with 
results as shown in Figure 4.7. The measurement of NO release at pH 7.4 has not 
been done due to COVID-19 lockdown, this will have to be done in the future. 
According to the previous NO release data analysis in Chapter 3, the NO release of Ti 
foams at pH 7.4 is assumed to follow the same trend (t[NO]: 5% > 20% > 1% > 10%; 
[NO]m: 5% > 1% > 20% > 10%) at pH 4 but with lower and longer releasing. The 
following analysis of planktonic bacterial growth inhibition are also based on this 
assumption. 
NO release Ti foams displayed effective antimicrobial activity on planktonic E. coli 
during the 4 and 24 h incubation periods as shown in Figure 4.7(a). After 4 h 
incubation, compared with the control group m_Ti, sample m_Ti/NO didn’t 
presented significantly different reduction on planktonic E. coli proliferation, sample 
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1%AUTES/NO presented ~0.8-log reduction, sample 5%AUTES/NO had 0.6-log 
reduction, 10%AUTES/NO displayed 1.1-log reduction and 20%AUTES/NO showed no 
significantly different reduction on planktonic E. coli growth. After 24 h incubation, 
due to the fast recovery growth of E. coli, foams those without NO releasing have 
displayed significant number of colonies. All the AUTES/NO foams presented efficient 
prevention of planktonic E. coli growth. Furthermore, 5%AUTES/NO showed the 
highest prevention with 2.5-log and 1.2-log, respectively compared to m_Ti and 
m_Ti/NO, after 24 h.    
NO release Ti foams also displayed effective antimicrobial activity on S. aureus during 
the 4 and 24 h incubation periods as shown in Figure 4.7(b). After 4 h incubation, 
compared with the control group m_Ti, sample m_Ti/NO presented no significantly 
different reduction on planktonic S. aureus growth, sample 5%AUTES/NO had 1.1-log 
reduction which is the largest, while sample 1%AUTES/NO, sample 10%AUTES/NO 
and 20%AUTES/NO showed ~0.9-log reduction. After 24 h incubation, due to the fast 
recovery growth of bacteria, foams those without NO releasing have displayed 
significant number of colonies. 1%AUTES/NO and 5%AUTES/NO showed ~1 log 







Figure 4.7: Planktonic a) E. coli and b) S. aureus colonies formation on the NO release 
Ti foams after 4 and 24 h incubation. *p < 0.05 from control; #p <0.05 from the 
corresponding silane concentration with no diazeniumdiolates functionalisation. 
(NOTE: two runs on both bacteria have been done here) 
 
AUTES/NO foams displayed good growth inhibition against both planktonic E. coli 
and S. aureus in 4 and 24 h incubation time points. It can be seen that planktonic E. 
coli showed highly sensitive to NO released from the foams in the long-term 
incubation, which is corresponding to the NO releasing kinetic of AUTES/NO foams. 
In addition, planktonic S. aureus growth has been notably inhibited in 4 h incubation 
and around 1 log reduction (99% inhibition) after 24 h. Once again these, 






4.3.3.3 Bacterial Cell Viability 
Confocal microscopy was used to evaluate the effect of NO releasing from the foams 
on bacterial cell viability in 4 h culture. E. coli and S. aureus were stained with 
Live/Dead assays, where live and dead cells display green and red, respectively, with 
results shown in Figure 4.8. 1%AUTES/NO and 5%AUTES/NO, which displayed 
excellent biofilm prevention and planktonic bacterial growth inhibition, were 
selected to use in the test. m_Ti and m_Ti/NO were used as control groups.  





Figure 4.8: Fluorescence images of live/dead i) E. coli and ii) S. aureus on a) m_Ti, b) 
m_Ti/NO, c) 1%AUTES/NO and d) 5%AUTES/NO after 4 h incubation. Representative 




Cultures with m_Ti and m_Ti/NO (Figure 4.8 a(i) and b(i)) showed mainly live E. coli 
and exhibited fewer dead cells, compared with 1%AUTES/NO (Figure 4.8 c(i)) and 
5%AUTES/NO (Figure 4.8 d(i)). It can be seen that with the increase of the silanisation 
concentration, leading to a higher NO payload contributes to the higher killing 
efficacy of the bacteria and the presentation of more dead cells (red stains) on 
1%AUTES/NO and 5%AUTES/NO. These results are in corroboration with that of the 
biofilm and planktonic experiments given above.    
m_Ti and m_Ti/NO (Figure 4.8 a(ii) and b(ii)) presented numerous live S. aureus on 
surfaces, while fewer live cells were seen on 1%AUTES/NO (not significantly less, 
Figure 4.8 c(ii)). On 5%AUTES/NO (Figure 4.8 d(ii)), more dispersed dead S. aureus 
(red) and less live S. aureus (green) cells were captured, implying the 5%AUTES/NO 
foam reduced cell viability of the attached S. aureus. 
4.4 Conclusion 
In this chapter, Ti foams have been fabricated with a novel LCS process to determine 
the feasibility of using this manufacturing technique for the fabrication of 
antimicrobial bone integrating implants. The best antimicrobial coating from the 
previous chapter has been selected and used to study the antimicrobial efficacy of 
the Ti foams with various concentration of the silane layer. NO releasing foams 
displayed high instantaneous NO release and steady long-term release when the 
concentration of silane is < 5%. The inhibition to the biofilm and planktonic bacterial 
growth correspond to the efficient releasing period and the instantaneous NO 
concentration of the NO release foams. Future work on this project will focus on 
determining the osteogenic potential of these scaffolds. 
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Chapter 5 Fabrication and Characterisation of Antimicrobial 
Guided Bone Regeneration (GBR) Electrospun Membranes  
5.1 Introduction 
Reconstruction of bone defects that are a result of trauma, infection, tumour 
resection or congenital malformations remain challenging in orthopaedic clinical 
practices.301-302 Although human bone tissue has self-healing potential, the 
regeneration of osseous defects is often hindered by the invasion of non-functional 
soft tissue generated by the penetration of fibrous or epithelial tissue.303 Guided 
Bone Regeneration (GBR) has been established as an effective therapy to circumvent 
this problem by using porous membranes that can simultaneously act as a physical 
barrier to prevent the ingrowth of fibrous tissue, whilst allowing for active tissue 
regeneration.181, 304-305 The efficacy of the GBR approach depends on a few factors: 
the membranes should be flexible enough to overlay the tissue defect, provide the 
appropriate mechanical properties and degradation profile and mimic the natural 
extracellular matrix (ECM) in order to allow for cell adhesion and proliferation which 
can eliminate the need for surgical removal.306-309  
Electrospinning is a promising technique for the fabrication of GBR membrane with 
notable advantages, including the availability of a wide range of polymers, the ability 
to control the diameter and alignment of fibres, space maintenance, high porosity, 
malleability and multifunctionality of the produced membranes.236, 309-311 Many 
studies have investigated electrospun membranes fabricated from a combination of 
two or more ingredients, such as bioactive glass/polycaprolactone (PCL),247, 312 
poly(L-lactide) (PLLA)/chitosan313 and collagen/chitosan/polyurethane (TPU) 
membrane,314 with the purpose of achieving higher osteoconductivity, better 
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biodegradation and fitted mechanical properties that are not available in a single 
component. Although electrospun PCL membranes are used extensively for bone 
regeneration applications due to their excellent mechanical properties, its inherently 
high hydrophobicity prohibits proactive biological responses such as cell adhesion, 
migration, proliferation and differentiation.315 Gelatine, a natural biopolymer 
derived from collagen, has good biocompatibility, non-immunogenicity, but low 
mechanical strength and fast degradation.316 Hence, the combination of PCL/gelatine 
electrospun membranes can offer advantages of both polymers: mechanical 
strength, degradation and biocompatibility.  
While tissue regeneration via GBR may be effective, potential implant failure can 
occur due to bacterial infections. Conventional treatment of these infections can 
include either systemic or localised delivery of antibiotics, which is problematic given 
the current rise in multidrug resistant bacteria. Thus, there is an urgent need to tackle 
infection with novel antimicrobials that do not lead to antimicrobial resistance, whilst 
allowing for active tissue regeneration. Nitric oxide (NO), is a promising alternative 
to antibiotics as it has shown potent antibacterial activity and will not lead to the 
development of antimicrobial resistance in bacteria due to the several pathways of 
inactivation.287, 317 It has been previously demonstrated that N-diazeniumdiolates are 
an effective and versatile NO donor that can be easily tethered onto amino-
functional groups that are capable of spontaneously releasing NO under physiological 
conditions.36, 141  
This chapter reports on the fabrication of electrospun PCL/gelatine membranes 
tethered with the antimicrobial NO to allow for active GBR, whilst simultaneously 
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preventing infection. Electrospun nanofibrous membranes were first prepared by 
varying the ratios of PCL and gelatine. The composite membranes were then 
crosslinked with genipin a natural nontoxic agent which demonstrates lower cellular 
toxicity than the traditional crosslinking agents such as glutaraldehyde318 and 
EDC/NHS.319 This chapter is to study (i) modulation of the fibre morphology and NO 
payload profile of the membrane by varying the ratio of PCL:gelatine and the degree 
of crosslinking and (ii) decrease of bacterial adhesion by tethering of NO onto the 
membranes.  
5.2 Materials and Methods 
5.2.1 Materials 
2, 2, 2-trifluoroethanol (TFE) solvent, gelatine (GT) (gel strength 300 g Bloom, Type 
A), Poly(ε-caprolactone) (PCL) (Mn: 80, 000 g·mol-1), genipin (≥98% ), Luria-Bertani 
(LB) broth and agar were purchased from Merk KGaA (Darmstadt, Germany) and 
used as received. All common, analytical grade laboratory solvents and salts, 
including ethanol, acetic acid (HAc), hydrochloric acid (HCl), disodium phosphate and 
sodium acetate (NaAc), were from Merk KGaA (Darmstadt, Germany) and used as 
received. The chemical structures of the selected polymers for electrospinning and 





Figure 5.1: Chemical structure of selected polymers and crosslinker. (A): Gelatine 












Sample nomenclature is as follows: (a) In the liquid phase, solutions only containing 
PCL are termed as PCL; solutions only containing GT are termed as GT; solution 
containing PCL: GT termed as both shorts with numbers, for example, mixed solution 
with a PCL: GT mass ratio of 75:25 termed as P75G25. (b) For electrospun samples, 
use the same nomenclature as in (a). (c) The crosslinked samples, for example, 
crosslinked P75G25 is termed as c_P75G25. (d) Diazeniumdiolate functionalised 
samples are termed as PCL/NO, GT/NO, P25G75/NO, P50G50/NO, P75G25/NO, 
c_PCL/NO, c_GT/NO, c_P25G75/NO, c_P50G50/NO and c_P75G25/NO. Summarised 
in Table 5.1. 
 
Table 5.1: Ingredients of the electrospun membranes and the usage of crosslinking 
agent. 
Sample PCL/ wt% Gelatine/ wt% Genipin 
PCL 100 0 - 
P75G25 75 25 - 
P50G50 50 50 - 
P25G75 25 75 - 
GT 0 100 - 
c_PCL 100 0 + 
c_P75G25 75 25 + 
c_P50G50 50 50 + 
c_P25G75 25 75 + 
c_GT 0 100 + 
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5.2.2 Electrospinning Solution Preparation 
The polymer solutions of PCL and GT were prepared separately in TFE (10 % wt) by 
stirring at room temperature. After both polymers were dissolved completely in the 
solvent, the two solutions were blended at weight ratios (PCL solution: GT solution) 
of 75:25, 50:50 and 25:75. The mixture was turbid as a result of the phase separation 
of PCL and GT. Therefore, a few drops of HAc were added to the solution followed by 
further stirring (4 h) in order to obtain a homogenous PCL/GT solution for 
electrospinning.320 The required amount of added HAc in reducing the phase 
separation was determined by measuring the light transmittance (%) of 5 ml P50G50 
solution with a UV-vis spectrophotometer at a wavelength range from 400-800 nm 
after adding specific volumes of HAc.     
5.2.3 Electrospinning  
The parameters used in this chapter were based on a previous research.320 The flow 
rate was subsequently optimised to produce beads-free fibres on an electrospinner 
(IME, Waalre, Netherland). After stirring for 4 h, polymer solutions were transferred 
into a 5 ml plastic syringe fitted with a blunt-ended needle (diameter of 0.4 mm, 
reciprocating motion speed of 10 mm/s over a distance of 50 mm) and the polymer 
solution flow rate was set to of 2 ml/h. A cylindrical grounded mandrel (diameter = 
90 mm, height = 180 mm), coated with aluminium foil, at a distance of 185 mm away 
from the needle tip rotated at 200 RPM. A high voltage of 20 kV was applied between 
the needle and the collector. Membranes were collected after electrospinning for 
120±10 mins in a climate control system with a relative humidity of 70% and 
temperature of 23 °C. The collected membranes were dried in the fume hood in air 
for 7 days to remove any remaining solvent.  
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The electrospun scaffolds were crosslinked for 24 h by immersion in 2% (w/v) 
genipin/ethanol solution. After crosslinking, these scaffolds were washed with 
ethanol 3 x 5 mins to remove residual genipin. The crosslinked scaffolds were dried 
in vacuum for 3 days to eliminate any leftover solvent. All the scaffolds were stored 
in a vacuum desiccator covered with foil until use to prevent degradation. 
5.2.4 Synthesis of NO-Releasing Electrospun Membranes 
Electrospun membranes were functionalised with diazeniumdiolates in an in-house 
built stainless-steel NO reactor as previously reported.141 Briefly, the reactor 
chamber was purged with 6 bar argon (BOC, Guildford, UK) for 5 mins (3 x) and 10 
mins (3 x) to remove atmospheric oxygen and water. Then nitric oxide (NO) (BOC, 
Guildford, UK) was introduced into the reactor at 5 bar for 3 days. At the end of this 
time, residual NO was removed by flushing the chamber with 6 bar argon for 5 mins 
(2 x) and 10 mins (2 x). Diazeniumdiolate functionalised membranes were then 
stored at -20°C until use. It should be noted that as PCL does not possess any amine 
functionality, there is no possibility of forming N-diazeniumdiolates, and as such it is 
the control group in NO release tests. The nomenclature is kept as PCL/NO for 
consistency and ease of readership. 
5.2.5 Scanning Electron Microscopy (SEM) 
The morphology of the fibres was examined by SEM. Membranes firstly were cut into 
10 x 10 mm2 and coated with gold by using Q150T ES sputter coater. Images were 
captured on a JSM 7001F field emission scanning electron microscope with a voltage 
of 10.0 kV. The diameter analysis of the fibres was performed by randomly picking 
up 20 fibres from each material enlargement SEM images and measuring in Image J.     
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5.2.6 Contact Angle 
Surface wettability was determined by measuring static contact angles with 
Attension ThetaLite. The sessile drop method was used and contact angle 
measurement images were taken using OneAttension software (Biolin Scientific, 
Västra Frölunda, Sweden). The image began to be captured from when the drop 
contacted with the surfaces and was continuously captured for 10 seconds. All 
membranes were measured in triplicates.    
5.2.7 Fourier-transform Infrared Spectroscopy (FTIR) 
The FTIR spectra of the electrospun membranes was analysed using a PerkinElmer 
frontier IR system over the range of 500-4000 cm-1 at a scanning resolution of 4 cm-1.  
5.2.8 Chemiluminescence 
Nitric oxide release from membranes was measured using a Sievers 280i 
Chemiluminescence Nitric Oxide Analyser (NOA280i, GE, USA). The diazeniumdiolate 
functionalised samples (10 x10 mm2) were immersed in 5 ml of acetic acid buffer (pH 
4) or phosphate buffered saline (PBS; pH 7.4) at room temperature in a three-neck 
round bottom flask. Nitrogen gas was continuously passed through the headspace of 
the vessel to bubble the buffer at a flow rate of 200 mL/min. A vacuum pump 
connected with the NOA was used to draw the mixed gases in to the reaction cell and 
maintain the pressure of the reaction cell. Nitric oxide release was measured at 




5.2.9 Antimicrobial Assays 
5.2.9.1 LB Broth and Agar Plates Preparation  
The LB broth and agar plates preparation have been the same as described in Chapter 
3 section 3.2.5.1.      
5.2.9.2 General Bacterial Culture 
Escherichia coli (E. coli) ATCC 10536 and Staphylococcus aureus (S. aureus) ATCC 
25923 were used to evaluate the antibacterial efficacy of the nitric oxide releasing 
membranes. The operation has been the same as described in Chapter 3 section 
3.2.5.2.  
5.2.9.3 Biofilms Colony Forming Unit (CFU) Assay on Adhered Bacteria 
The overnight cultures of E. coli and S. aureus were diluted to 1 x 106 CFU/mL in LB 
broth, according to the absorbance @600 nm and a 0.5 McFarland Standard.289 
Membranes (cut into 10 x 10 mm2) were placed in a 24 well-plate and 1 mL of diluted 
bacterial solution was added to each well before incubating at 37 °C to allow bacterial 
growth and biofilm formation. After 4 h incubation, membranes were gently washed 
with PBS once to remove any unattached planktonic bacteria and then 1 mL of fresh 
LB broth was used to remove and re-suspend the biofilms. The bacterial CFU was 
determined after serial dilution of the bacterial suspension using the Miles and Misra 
method on LB agar plates.271  
5.2.9.4 Antimicrobial Activity Assay on Planktonic Bacteria 
The overnight cultures of E. coli and S. aureus were diluted to 1 x 106 CFU/mL in LB 
broth, according to the absorbance @600 nm and a 0.5 McFarland Standard.289 
Membranes (cut into 10 x 10 mm2) were placed in a 24 well-plate and 1 mL of diluted 
bacterial solution was added to each well before incubating at 37 °C to allow bacterial 
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growth. After 4 h incubation, the liquids in the well-plates were removed to another 
aseptic well-plate and serially diluted with LB broth. The antimicrobial activity against 
planktonic bacteria was determined using the Miles and Misra method on LB agar 
plates.271 
5.2.10 Statistical Analysis  
One-way analysis of variance (ANOVA) was used to analyse the differences among 
various treatment samples. The Student-Newman-Keuls (SNK) method was carried 
out to determine significance between treatment types. All data were collected in 
triplicate and displayed as Mean ± Standard Deviation. A value of p < 0.05 was taken 
as being statistically significant.  
5.3 Results and Discussion 
5.3.1 Phase Separation of Electrospinning Solutions 
5.3.1.1 Preparation of Solutions 
In this chapter, composite PCL/gelatine fibrous membranes with 5 different ratios 
were fabricated by electrospinning under consistent parameters such as voltage, 
flow rate, needle collector distance and humidity. Fabrication of consistent 
nanofibrous membranes was challenging given that phase separation occurs as 
gelatine is a hydrophilic polymer and dissolves easily in water and PCL is a 
hydrophobic polymer preferring organic solvents.321  
TFE was used as a solvent to dissolve PCL and GT to form transparent solutions. The 
5 different ratios of polymers, with mass ratios of PCL:GT at 100:0, 75:25, 50:50, 
25:75 and 0:100, displayed different phase separation behaviours, depending on the 
relative proportions of the two polymer components (Figure 5.2). It is commonly 
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observed that the interaction between the two polymer chains with each other can 
lead to phase separation behaviour.322-324 In this chapter, it was found that the mixed 
PCL and GT solutions become opaque and gradually separate into two phases after a 
period of time. Qualitative observation of the 3 mixed solutions, showed that P75G25 
had the least phase separation in comparison to P5050 and P25G75 (Figure 5.2). 
There was a clear phase separation interface in both P50G50 and P25G75 solutions, 
with greater amounts of precipitate being observed after 24 h as the gelatine 
concentration was increased.  
 
 
Figure 5.2: Photographs of the PCL:GT solutions (mass ratios of 100:0, 75:25, 50:50, 




The solution P50G50 was left to rest for selected time periods over a 24 h interval 
(Figure 5.3). The turbidity of the mixture solution lasted for more than 6 h and a clear 
separation interface appeared after 24 h. This was important to observe as the 
electrospinning process takes place over a few hours, and as such any phase 
separation could most likely affect quality and the consistency of the fibres.  
 
 
Figure 5.3: Photographs of the PCL:GT solutions at a mass ratio of 50:50 after being 




5.3.1.2 Acetic-Acid Mediated Solutions 
Acetic acid (HAc) was used to mitigate the effect of phase separation caused by the 
immiscibility of the polymer chains. Upon addition of HAc (20 µl), the PCL/GT 
solutions turned transparent and clear after stirring. There was no observed turbidity 
in solution after 1-week storage in a glass vial. The turbidity measured in terms of the 
light transmittance of the P50G50 solutions was observed to be mediated with 
different amounts of HAc (10 - 30 µl) as seen in Figure 5.4. The transmittance 
percentage of P50G50 was close to 0, due to the opacity of the mixed solution. With 
the increasing amount of HAc, P50G50 solution displayed higher transmittance, due 






Figure 5.4: Light transmittance of the PCL/GT solution with a mass ratio of 50:50 
before and after acetic acid mediating.  
 
 
PCL and GT are inherently immiscible polymers and given that there is a sol-gel 
transition of GT, a mixture of these two polymers will result in the opacity of the 
solution, followed by gradual separation of the layers as seen in Figure 5.2. GT is 
known to its lowest solubility in mixture solution and therefore precipitate at its 
isoelectric point (IEP).325-326 A change in pH by the addition of small amounts of HAc 
will move the pH of the solution away from the IEP. This will prevent the sol-gel 
transition of gelatine an make it more soluble in the mixture. This phase separation 
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behaviour also has been previously observed by others.321, 327-328 The introduction of 
small amounts of acetic acid (0.2~0.6% v/v of TFE) increased the transmittance of the 
turbid mixture solution of P50G50. Therefore, an acetic acid mediated system has 
been utilised to achieve a lower pH value of the mixture solution than its IEP, 
resulting in effective reduction of the sol-gel transition. Moreover, at more acidic pH 
the amino groups in GT are more positively charged and therefore repel each other 
allowing for more entanglement with the PCL chains.329  
5.3.2 Characterisation of Electrospun Fibres 
5.3.2.1 Morphology of Fibres 
The well dispersed PCL/GT solutions with different mass ratios of PCL and GT were 
electrospun successfully to obtain bead-free fibrous membranes (shown in Figure 5.5 
i). These electrospun fibres containing PCL were smooth. The average diameter of 
the fibres ranged from 0.7-1.2 µm (shown in Table 5.2). The diameter of the fibres 
was dependent on the ratios of the polymers to each other, with an increasing 
concentration of GT resulting in smaller fibre diameters. The pure GT samples (Figure 
5.5 i) displayed agglutination between fibres. This agglutination can be explained by 
the fact that the electrospinning process can be a lengthy process which can result in 
the GT-induced phase separation, thereby affecting the fibre structure.  
The SEM micrographs of the genipin-crosslinked nanofibrous membranes are shown 
in Figure 5.5 ii. The same trend in the fibre diameters (displayed in Table 5.2) of the 
non-crosslinked samples was seen once again; the samples with increasing ratios of 
GT displayed smaller fibres overall. There is no significant difference in the diameter 
of the fibres after crosslinking by genipin. Of high interest is that the c_GT fibrous 
membranes displayed less agglutinating when compared with the pre-crosslinking 
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GT. One explanation for this observation is that the genipin might slightly change the 
surface hydrophilicity of the GT membranes, resulting in the slower moisture 
absorbance from the c_GT membrane. A more in-depth discussion of the effect of 






Figure 5.5: Scanning Electron Microscopy (SEM) of electrospun PCL/GT membranes, 
with a series mass ratio of 100:0, 75:25, 50:50, 25:75 and 0:100, (i) before and (ii) 
116 
 
after crosslinking in genipin. Inserts are enlargements of the figures. The scale bar 
represents 10 µm in figures and inserts. 
 
Table 5.2: Fibre contents, crosslinking agent, and fibre diameter of electrospun 
membranes. 
Sample  PCL wt% Gelatine wt% genipin Fibre diameter (µm) 
PCL 100 0 - 1±0.3 
P75G25 75 25 - 1.2±0.4 
P50G50 50 50 - 0.8±0.2 
P25G75 25 75 - 0.7±0.2 
GT 0 100 - 2±0.4 
c_PCL 100 0 + 1.1±0.3 
c_P75G25 75 25 + 1.1±0.5 
c_P50G50 50 50 + 1.2±0.2 
c_P25G75 25 75 + 0.6±0.1 
c_GT 0 100 + 2.2±0.1 
 
5.3.2.2 Wettability: Contact Angle 
Static water contact angles using the sessile drop technique were performed to 
characterise the wettability of the electrospun nanofibres. In general, a more 
hydrophilic or wettable surface is known to have a more positive impact on 
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promoting cell adhesion.330 The contact angles of both non-crosslinking and 
crosslinking electrospun membranes were measured for the initial 10 s of contact 
with a water droplet (Figure 5.6). PCL is known to be hydrophobic and has shown a 
contact angle of 130°. For the non-crosslinked samples, the addition of the more 
hydrophilic GT component in the electrospun fibrous membranes, causes a 
significant decrease in contact angle. This is attributed to the increase in the amine 





Figure 5.6: Optical images of water droplets on the electrospun membranes for the 
initial 10 s during the measurement of water contact angle. Images were taken every 






After crosslinking with genipin, the same trend of a steep decrease in contact angle 
is observed when going from pure PCL to pure gelatine, implying that the genipin has 
no effect on wettability of the electrospun fibrous membranes with higher PCL 
concentrations. Nevertheless, the shape of water drops maintains longer on 
c_P50G50, c_P25G75 and c_GT, when compared to P50G50, P25G75 and GT, 
respectively. On one hand, porous microstructure played a role in influencing the 
liquid-solid interface in contact angle measurement. Denser porous microstructures 
can be seen on c_P50G50, c_P25G75 and c_GT (enlarged images in Figure 5.5), 
resulting in surfaces with higher contact angles in the initial seconds. On the other, 
the surface wettability of these membranes with higher gelatine concentration was 
mediated by the crosslinking mechanism of genipin. The crosslinking mechanism of 
genipin includes two reactions (shown in Figure 5.7), involving different sites on the 
genipin molecule.331 The first reaction is a nucleophilic substitution reaction between 
the -NH2 and -COOCH3, leading to a replacement of the ester group on the genipin 
molecule by a secondary amide linkage. The next reaction is a nucleophilic attack of 
the genipin C3 carbon atom from the primary amine group of gelatine to form an 
intermediate aldehyde group. The just formed secondary amine reacts with the 
aldehyde group to form a heterocyclic compound. The lack of change in water 
contact angle, which measured after seconds, between the non-crosslinked and 
crosslinked fibres was also observed by Zhang and coworkers320, 332 who determined 
that only amino groups present in a small quantity were crosslinked leaving the 
carboxylic groups.  
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Figure 5.7: Crosslinking mechanism at different sites on genipin molecule with 
primary amine. Images reproduced from Butler et al.331 with permission from John 
Wiley and Sons. 
 
5.3.2.3 Chemistry Structure: FTIR 
FTIR analysis was used to characterise the chemical bonds of PCL and GT in the 
membranes (Figure 5.8). PCL can be easily identified from its strong bands at ~2949 
cm-1 (Figure 5.7 dash line a) and 2865 cm-1 (Figure 5.7 dash line b) corresponding to 
the stretching vibration of asymmetric and symmetric CH2 bonds, respectively. The 
peak at 1727 cm-1 corresponds to the carbonyl stretching of PCL .333 For GT, the FTIR 
spectrum displays peaks at ~1650 cm-1 (amide I, Figure 5.7 dash line c) and ~1540 
cm-1 (amide II, Figure 5.7 dash line d) corresponding to the stretching vibration of 
C=O bond and the coupling vibrations of N-H and C-N, respectively.321, 334 The FTIR 
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spectrum of the hybrid nanofibrous membranes include the characteristic peaks of 




Figure 5.8: FTIR spectra of different electrospun fibrous membranes. 
 
5.3.3 Chemiluminescence: Measurement and Mechanism of NO Release 
The NO payload from the diazeniumdiolate-modified membranes was determined by 
using a chemiluminescence nitric oxide analyser in acetic acid and PBS buffers at pH 
4 and 7.4, respectively. The NO release profiles of non-crosslinked electrospun 
membranes are shown in Figure 5.9. The kinetics of NO release, including the total 
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concentration of NO (t[NO]), maximum instantaneous NO release concentration 
([NO]m), time required to reach [NO]m (tm), and NO release duration (td), were 
determined from each membrane, and the values are summarised in Table 5.3. The 
NO payload and release kinetics were dependent upon the gelatine content 
percentage of the membranes, the pH of the measuring buffers and crosslinking. But 
due to the COVID-19 lockdown, the release profiles of the crosslinking membranes 
were not able to be measured unfortunately.  
GT/NO: At pH 4, GT/NO membranes released NO at a maximum instantaneous NO 
concentration of 27.6 µM·s-1·cm-2 at 3 min with a total NO release concentration of 
40 mM within 16 h. At pH 7.4, the total NO release of GT/NO was less than at pH 4, 
with a concentration of 15 mM and a lower maximum instantaneous NO 
concentration of 10.4 µM·s-1·cm-2.   
P25G75/NO: At pH 4, P25G75/NO membranes released NO at a maximum 
instantaneous NO concentration of 3.0 µM·s-1·cm-2 at 98 min with a total NO release 
concentration of 64 mM within 16 h. At pH 7.4, the total NO release of P25G75/NO 
was less than at pH 4, with a concentration of 8.4 mM and a lower maximum 
instantaneous NO concentration of 7.8 µM·s-1·cm-2.  
 P50G50/NO: At pH 4, P50G50/NO membranes released NO at a maximum 
instantaneous NO concentration of 9.7 µM·s-1·cm-2 at 5 min with a total NO release 
concentration of 37 mM within 16 h. At pH 7.4, the total NO release of P50G50/NO 
was less than at pH 4, with a concentration of 8.7 mM and a lower maximum 
instantaneous NO concentration of 6.1 µM·s-1·cm-2. 
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P75G25/NO: At pH 4, P75G25/NO membranes released NO at a maximum 
instantaneous NO concentration of 9.2 µM·s-1·cm-2 at 5 min with a total NO release 
concentration of 25 mM within 16 h. At pH 7.4, the total NO release of P75G25/NO 
was less than at pH 4, with a concentration of 0.3 mM and a lower maximum 
instantaneous NO concentration of 0.5 µM·s-1·cm-2. 
PCL/NO: As there is no nitrogen in the backbone of PCL, it was expected that no 
diazeniumdiolate formation would take place and hence, no NO release. However, a 
small amount of NO has been measured at both pH 4 and 7.4, that is resulting from 
free NO gas molecules physisorbed on the surface of membranes.  
 
The NO payload and release kinetics were dependent upon the ratio of gelatine 
content in the membranes and the pH of the measuring buffers. The GT/NO 
membranes released a lower total NO concentration than P25G75/NO at pH 4 but 
this trend was reversed at pH 7.4. This could be due to the loss of gelatine during 
sample preparation for chemiluminescence. That, it is of more challenge to fully 
remove GT membranes from the supported foil surfaces, when compare to the 
removal of PCL-contained membranes. With more time, an improved mean to ensure 
consistency of the membranes in size would be considered before 
chemiluminescence. Lower NO concentration was expected from the membranes at 
pH 4 based on the mechanistic study presented in Chapter 3. N-diazeniumdiolates 
formed on primary amine sites decompose to HNO and NO with the product ratio 
dependent on the pH and the basicity of the nitroso oxygen formed.268 Therefore N-
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diazeniumdiolates should decompose entirely to NO at pH 4 and a mixture of HNO 
an HNO at pH 7.4.  
 
Figure 5.9: Chemiluminescence NO release profiles of diazeniumdiolate-
functionalised membranes after 4 h and the inset is rescaling of the first 10 min at a) 





Table 5.3: NO release properties for diazeniumdiolate-functionalised membranes in 
pH 4 and 7.4. 
pH membrane 
t[NO] [NO]m tm td 
(mM) (µM·s-1·cm-2) (min) (h) 
4 
GT/NO 40 27.6 3 16+ 
P25G75/NO 64 3.0 98 16+ 
P50G50/NO 37 9.7 5 16+ 
P75G25/NO 25 9.2 5 16+ 
PCL/NO 0.1 0.4 9 - 
7.4 
GT/NO 15 10.4 2.5 10+ 
P25G75/NO 8.4 7.8 4.6 10+ 
P50G50/NO 8.7 6.1 1.8 10+ 
P75G25/NO 0.3 0.5 6 10+ 
PCL/NO 0.07 0.4 6.1 - 
 
5.3.4 Antimicrobial Analysis 
5.3.4.1 Biofilm Inhibition  
Bacterial biofilms cause up to 80% of nosocomial infections and once a biofilm forms, 
the infection is very difficult to eradicate.295 One of the most effective means to 
prevent the formation of biofilm is to reduce or stop the initial adhesion of bacteria 
onto surfaces. Gram-negative E. coli and gram-positive S. aureus, which are relevant 
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to orthopaedic implant infections,296-297 were selected to measure the antimicrobial 
activity of the NO releasing electrospun membranes.  
 
Non-Crosslinked Membranes 
The prevention of biofilm formation on the various non-crosslinked membranes at 4 
h was determined by biofilm CFU assay, with the results shown in Figure 5.10. 
Bacteria were incubated on the surfaces for 4 h in LB broth to allow for biofilms to 
form, followed by the enumeration of the remaining viable bacterial colonies to 
analyse the efficacy of the NO-release. The result of the assay performed against E. 
coli is shown in Figure 5.10 a. GT/NO and P25G75/NO membranes both displayed a 
~1.3-log reduction of E. coli adhesion. P50G50/NO displayed ~0.9-log reduction from 
4×105 CFU/ml to 3×104 CFU/ml. Both P75G25/NO and PCL/NO membranes showed 
no significant difference of E. coli adhesion compared with P75G25 and PCL. The 
results of the biofilm CFU assay with E. coli are in agreement with the NO release 
profiles in Figure 5.9 showing that NO release correlated directly to antimicrobial 
activity, i.e. GT/NO has the largest NO payload, followed by P25G75/NO and 
P50G50/NO.  
The results of the biofilm CFU assay performed against S. aureus is shown in Figure 
5.10 b. GT/NO and P25G75/NO both displayed a ~0.8-log reduction in S. aureus 
adhesion. The P50G50/NO displayed a less than 0.4-log reduction. However, both 
P75G25/NO and PCL/NO membrane displayed large reductions in S. aureus adhesion, 
~1.1-log and ~1.5-log, respectively. The rationale for why these membranes perform 
better is unclear at the moment and extra experimental analysis has not been 
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possible due to the COVID-19 lockdown. The wettability, surface area and NO 




Figure 5.10: Viable bacterial colonies (CFU/mL) after 4 h of biofilm growth on non-
crosslinked electrospun membranes of a) E. coli and b) S. aureus. *p < 0.05 from PCL; 
#p <0.05 from the corresponding ratio with no diazeniumdiolate functionalisation. 
(Note: 3 runs for E. coli and 1 run for S. aureus have been done) 
 
Crosslinked membranes 
The prevention of biofilm formation on the various crosslinked membranes at 4 h 
was determined by biofilm CFU assay, with the results shown in Figure 5.11. The 
c_GT/NO displayed a reduction of E. coli adhesion from 1×105 CFU/ml to 1.5×103 
CFU/ml, which corresponds to a ~2-log reduction (shown in Figure 5.11 a). 
c_P25G75/NO displayed the highest reduction of E. coli adhesion with ~3-log. The 
c_P50G50/NO, c_P75G25/NO and c_PCL/NO membranes showed no significant 
difference in E. coli adhesion compared with the control samples. It can be clearly 
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seen that crosslinking largely improved the antimicrobial efficacy of both c_GT/NO 
and c_P25G75/NO, which would be due to the increasing of NO payload after 
crosslinking.  
The results of biofilm CFU assay with S. aureus on the crosslinked membranes (Figure 
5.11 b) showed a similar trend with of that of E. coli. The c_GT/NO and c_P25G75/NO 
membranes displayed a ~4-log reduction which corresponds to the highest reduction 
for all the membranes. The c_P50G50/NO, P75G25/NO and PCL/NO membranes 
showed ~2-log reduction in S. aureus adhesion. Once again as with the S. aureus 
experiments above an improved antimicrobial efficacy of both c_GT/NO and 
c_P25G75/NO was observed probably due to the increasing of NO payload after 
crosslinking. Unfortunately, the chemiluminescence measurements of crosslinked 
membranes were not completed prior to lockdown and this is needed for a further 
discussion of the results. However, it can be hypothesised (based on what has been 
observed in Chapter 3) that crosslinking creates more secondary amines (amides) 
which are known to be more stable and have higher and longer NO releasing profiles 







Figure 5.11: Viable bacterial colonies (CFU/mL) after 4 h of biofilm growth on 
crosslinked electrospun membranes of a) E. coli and b) S. aureus. *p < 0.05 from PCL; 
#p <0.05 from the corresponding ratio with no diazeniumdiolates functionalisation. 
(Note: 2 runs for E. coli and 2 runs for S. aureus) 
 
5.3.4.2 Antimicrobial Activity on Planktonic Bacteria 
Non-Crosslinked Membranes 
The prevention of planktonic bacterial growth in solution with the presence of the 
non-crosslinked electrospun membranes at 4 h was determined by using a spread 
plate CFU assay and the results are displayed in Figure 5.12. The antimicrobial activity 
of membranes tested against E. coli (Figure 5.12 a) directly correlate with the payload 
NO release presented in Figure 5.9. The GT/NO membrane displayed a reduction of 
planktonic E. coli growth from 3.5×105 CFU/ml to 3.5×103 CFU/ml, corresponding to 
a 2-log reduction. The P25G75/NO membrane displayed ~1.5-log reduction in 
planktonic E. coli growth. The P50G50/NO P75G25/NO membranes displayed a 1 log 
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and ~0.8 log reduction, respectively. PCL/NO showed no significant difference in the 
planktonic E. coli growth. The prevention of planktonic E. coli growth directly 
correlates to the NO payload results (Figure 5.9), i.e. the higher the payload the 
better the antimicrobial efficacy.  
The results of prevention of planktonic S. aureus growth in solution in the presence 
of the non-crosslinked membranes (Figure 5.12 b) shows a different trend with of E. 
coli on NO release membranes at 4 h incubation. The GT/NO and P25G75/NO 
membranes displayed a~0.9 log reduction of planktonic S. aureus growth. The 
P50G50/NO, P75G25/NO, PCL/NO displayed 1.5, 1 and 0.7 log reduction, 
respectively. The investigation as to why S. aureus behaves differently to E. coli is not 
fully understood yet and COVID-19 lockdown has prevented us from exploring this 
further. Once again it is observed here that the GT membranes dissolve quite easily 
and are difficult to handle and thus may present a lower antimicrobial efficacy as a 







Figure 5.12: Planktonic a) E. coli and b) S. aureus growth in solution with the presence 
of the noncrosslinked electrospun membranes after 4 h incubation. *p < 0.05 from 
PCL; #p <0.05 from the corresponding ratio with no diazeniumdiolates 
functionalisation. (Note: 3 runs for E. coli and 1 run for S. aureus) 
 
Crosslinked Membranes 
The growth of planktonic bacteria at 4 h on crosslinked electrospun membranes is 
shown in Figure 5.13. The c_GT/NO membrane displayed a reduction of planktonic 
E. coli growth from 1×106 CFU/ml to 1.5×104 CFU/ml, which corresponds to a ~2-log 
reduction (shown in Figure 5.13 a). The c_P25G75/NO displayed the highest 
reduction of E. coli adhesion with ~3-log. The c_P50G50/NO, P75G25/NO and 
PCL/NO membranes showed less than 1 log reduction in planktonic E. coli growth. 
The crosslinking largely improved the antimicrobial efficiency of both c_GT/NO and 
c_P25G75/NO, by increasing the number of secondary amine (amide) functional 
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groups to facilitate increased NO loading which would be the rationale for the higher 
antimicrobial efficacy.  
The results against S. aureus (Figure 5.13 b) show a similar trend as against E. coli on 
crosslinked NO release membranes at 4 h incubation. The c_GT/NO membrane 
displayed the highest reduction of planktonic S. aureus growth from 1×106 CFU/ml 
to 1×104 CFU/ml, which corresponds to a ~2-log reduction. The c_P25G75/NO 
membrane displayed 1.5-log reduction of planktonic S. aureus growth. The 
c_P50G50/NO, c_P75G25/NO and c_PCL/NO showed no reduction or no significant 
difference in planktonic S. aureus growth. Once again, it can be concluded that 
crosslinking largely improved the antimicrobial efficacy of both c_GT/NO and 
c_P25G75/NO, due to the increasing of NO payload after crosslinking. Unfortunately, 
the chemiluminescence measurements of crosslinked membranes were not finished 




Figure 5.13: Planktonic a) E. coli and b) S. aureus growth in solution with the presence 
of the crosslinked electrospun membranes after 4 h incubation. *p < 0.05 from PCL; 
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#p <0.05 from the corresponding ratio with no diazeniumdiolates functionalisation. 
(Note: 2 runs for E. coli and 2 runs for S. aureus) 
 
5.4 Conclusion 
This chapter reports on the fabrication and the antimicrobial efficacy of crosslinked 
electrospun PCL/Gel membranes. The addition of acetic acid improved the phase 
separation issue during electrospinning which was instrumental to fabricating 
repeatable and reproducible membranes. SEM images indicated the fibre diameter 
of the membranes ranges from 0.7 to 1.2 µm. Genipin displayed no effect on the 
morphology of membranes but slightly decreased the hydrophilicity of the 
membranes at the initial contacting with water drop. The antimicrobial efficacy of 
the membranes was directly correlated to the mass ratio of gelatine in electrospun 
membranes. The higher the gelatine in the membrane the greater the NO loading 
which lead to a higher antimicrobial efficiency on E. coli and S. aureus. Moreover, 
crosslinking also had an effect on antimicrobial efficacy. Crosslinking provided more 
secondary amines which allowed for more stable and higher payloads of NO, thereby 




Chapter 6: Conclusions and Suggestions for Future Work  
6.1 Conclusions 
The aim of this thesis is to develop antimicrobial nitric oxide releasing materials for 
orthopaedic medical implants. The pathogenesis of many orthopaedic infections is 
related to the presence of biofilms on device surfaces, which are recalcitrant to 
conventional antibiotic therapy and causing antimicrobial resistance. In other word, 
the current clinical therapy for bacterial-related orthopaedic infections is the use of 
systematic antibiotics. Biofilm is a protective lifestyle of bacteria, and it has inherent 
tolerance to antibiotics therefore large doses of antibiotics are needed to achieve 
efficient treatment. The overuse of antibiotics has however resulted in rise of 
antimicrobial resistance of bacteria which necessitates larger doses and last resort 
antibiotics for treatment. However, the pipeline of antibiotics is depleting and there 
has been no new antibiotic developed for over 30 years.335-336 As such, is of great 
importance to develop alternative antimicrobial treatments that do no relay on 
antibiotics.  
The active agent selected during this thesis is NO as it is a potent antimicrobial agent 
that does not contribute to the development of antimicrobial resistance in bacteria. 
NO has been tethered onto the surfaces using an N-Diazeniumdiolate as a NO donor 
in this thesis. N-diazeniumdiolates are a versatile NO storage and delivery vehicle as 
the rate and payload of the therapeutic can be carefully controlled.  
The objectives have been achieved via the work described in the preceding three 
experimental chapters. Various of fabrication and functionalisation techniques have 
been carried out to develop NO releasing implants which were able to prevent the 
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adhesion of bacteria and the subsequent inhibited formation of biofilm on surfaces. 
Three implants surfaces used in the thesis were commercial Ti, LCS Ti foams and 
electrospun PCL/gelatine electrospun membranes. Different characterisations have 
been employed to measure and analysis these materials. SEM/AFM performed the 
morphology and topography of the surfaces. Contact angle, XPS and FTIR were used 
to analysis the wettability and surface chemistry, further confirming the targeted 
synthesis. The NO releasing kinetic has been performed via chemiluminescence. 
Biofilm CFU assays and bacterial viability tests against E. coli, S. aureus and P. 
aeruginosa were taken to evaluate the antibiofilm/antimicrobial property of the 
materials. The bone-integrating was tested on human primary bone cells. 
Firstly, in Chapter 3, NO releasing Ti surfaces were developed for antibiofilm and 
bone-integrating studies. Two different aminosilane precursors (AHAP3 and AUTES) 
were tethered onto commercially available flat Ti for subsequent functionalisation 
with NO. The structure of aminosilane precursors affected the resultants NO 
releasing properties in terms of payload and release kinetics, giving that both 
AHAP3/NO and AUTES/NO. The NO payloads and releasing kinetics were controlled 
in various ways, including the pKa of the amine, the class of amine groups, the layers 
of aminosilane precursors, the pH value of the release medium and the structure of 
substrate materials with larger surface areas. Therefore, at pH 4, AUTES/NO 
displayed the highest instantaneous NO concentration of 17.4 µM·s-1·cm-1 and the 
highest sum NO amount of 1883.6 µM. At pH 7.4, AUTES/NO still given the highest 
instantaneous NO concentration with value of 10.2 µM·s-1·cm-1, while the total NO 
release amount has been showing reduce to 476.2 µM. The antibiofilm/antimicrobial 
property of the materials dependent upon the NO payloads and releasing kinetics. 
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Low level NO release (in the case of using aminosilanes as precursors) displayed 
antimicrobial activity with a biofilm inhibition rate of up to 2.4 log in a short-term 
culture (i.e. 4-6 h incubation). In addition, the constancy of NO releasing for longer 
time benefited to efficient biofilm inhibition as well as planktonic bacterial viability 
in 24 h bacterial culture. However, there was a similar antibiofilm efficiency of both 
coatings against S. aureus and P. aeruginosa. Furthermore, low level NO release 
presented good bone-integrating on human primary bone cells. Compared to 
AHAP3/NO, AUTES/NO presented more recovered cells, indicating its lower 
cytotoxicity towards human primary bone cells after 7 days in culture.   
Secondly, in Chapter 4, Ti foams were fabricated with a novel LCS process, and the 
AUTES silnae coating (which was optimised the best performing silane in Chapter 3) 
have been used as aminosilane precursor for modifying the Ti foams. The layers of 
AUTES played roles on the NO releasing kinetics and the antimicrobial efficacy of the 
Ti foams. 5%AUTES/NO (the highest instantaneous NO release concentration of 6.2 
µM·s-1·cm-1 and the largest sum NO payload of 2.3 mM at pH 4) displayed the optimal 
antibiofilm/antimicrobial properties against both E. coli and S. aureus after 4 and 24 
h. 
Thirdly, in Chapter 5, PCL/gelatine biodegradable electrospun membranes were 
fabricated using varying ratios of each polymer. The effect of crosslinking on the 
degradability of the coatings were also investigated. The addition of PCL and 
crosslinking process improved the microstructure and the wettability of the 
membranes. Gelatine has amino functionality in the backbone of the polymer and 
this was used as point to tether the diazeniumdiolate NO donor molecule. The 
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membranes were characterised and analysed for the antimicrobial efficacy. The 
crosslinked PCL/gelatine membranes displayed higher antimicrobial efficacy on with 
planktonic and biofilm bacteria (S. aureus and E. coli). Compared with using silane 
coatings high level NO release (in the case of using gelatine as the precursor) 
displayed high level biofilm inhibition and planktonic bactericidal in 4 h incubation.       
In summary, three different bone implant models, ranging from flat titanium surfaces 
to porous titanium to electrospun membranes have been functionalised with the NO 
donor N-Diazeniumdiolate and have shown to be effective as antimicrobial materials 
for orthopaedic applications. These versatile materials are also promising as they use 
NO as the active agent that has not shown to develop resistance mechanisms in 





6.2 Suggestions for Future Work  
6.2.1 Race for the Surface: Bacterial-Mammalian Coculture Model  
The two major barriers for a successful bone implant surgery are biomaterials-
associated infections and tissue integration of the devices.337 Biomaterial related 
infections mainly result from the adhesion of planktonic bacteria onto device 
surfaces, subsequently colonise the surfaces and form biofilms. As it is known, biofilm 
is difficult to treat once it forms, and it is able to obstruct the attachment of tissue 
cells and against the host immune system.338-339 The successful tissue integrations 
dependent upon the interface reaction between device surfaces and tissue cells.337 
The competition between bacterial colonisation of implants and tissue cells 
integration with device surfaces was initially termed “the race for the surfaces” by 
Gristina in 1987.337 If the race is won by the tissue cells, then the surfaces are 
dominantly occupied by tissue cells and bacteria have a lower probability to form 
biofilms on the surfaces. Therefore, to mimic this in vivo condition, in vitro, future 
work would involve the development of a bacteria-cell coculture model. The biofilm 
inhibition efficacy on both NO release flat Ti surface and Ti foams has been evaluated 
against E. coli, S. aureus and P. aeruginosa, and these antimicrobial conditions have 
been shown to be non-cytotoxic to primary human osteoblast cells on flat Ti surfaces.  
6.2.2 Biodegradability and Mechanical Property of PCL/Gelatine Electrospun 
Membranes 
This section is the incomplete work due to COVID19 lockdown. Biodegradation and 
mechanical property are two of the strategy requirements that need to be 
considered when designing biodegradable membranes for guided bone 
regeneration. These experiments would need to be undertaken to complete this 
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study. There are concerns with the use of biomaterials with quick degradation rate 
as there will be a rapid loss of mechanical stability in situ and subsequently allowing 
undesirable cell type entering the regeneration area.340 Alternatively, a slow 
degradation could prevent tissue formation or result in stress shielding which would 
affect the integrity of the de novo tissue. As such this work needs to be extended in 
order to have the degradation rate of the membranes match the tissue regeneration 
rate.341 Once optimised membranes in terms of degradation rate, mechanical 
stability and antimicrobial efficacy are optimised, in vitro cytocompatibility studies 
will need to be carried out. 
6.2.3 Guided Stem Cell Differentiation of NO release PCL/Gelatine Electrospun 
Membranes  
Endogenous NO plays role in governing various physiological process and it is a 
versatile signalling molecule in mediating cellular functions.342 There is little or no 
research that has been carried on whether exogenous NO can affect the 
differentiation of mesenchymal stem cells. Once the NO releasing PCL/gelatine 
electrospun membranes have been optimised as in section 5.2.2, it is suggested to 
investigate study these membranes for guided bone regeneration using 
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